

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 870 832 A1**

(12)

# EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:  
14.10.1998 Bulletin 1998/42

(51) Int. Cl.<sup>6</sup>: **C12N 15/54**, **C12N 9/12**

(21) Application number: **96943336.6**

(86) International application number:  
**PCT/JP96/03869**

(22) Date of filing: **26.12.1996**

(87) International publication number:  
**WO 97/24444 (10.07.1997 Gazette 1997/30)**

(84) Designated Contracting States:  
**DE FR GB IT NL**

(30) Priority: **27.12.1995 JP 353778/95**

(71) Applicant: **TAKARA SHUZO CO. LTD.**  
**Kyoto-shi, Kyoto 612 (JP)**

(72) Inventors:  
• **UEMORI, Takashi**  
**Shiga 520-21 (JP)**

• **ISHINO, Yoshizumi**  
**Osaka 569 (JP)**  
• **KATO, Ikunoshin**  
**Kyoto 611 (JP)**

(74) Representative:  
**Schüssler, Andrea, Dr.**  
**Kanzlei Huber & Schüssler**  
**Truderinger Strasse 246**  
**81825 München (DE)**

## (54) **NOVEL DNA POLYMERASE**

(57) The present invention relates to a DNA polymerase possesses the properties of 1) exhibiting higher polymerase activity when assayed by using as a substrate a complex resulting from primer annealing to a single stranded template DNA, as compared to the case where an activated DNA is used as a substrate; 2) possessing a 3'→5' exonuclease activity; 3) being capable of amplifying a DNA fragment of about 20 kbp, in the case where polymerase chain reaction (PCR) is carried out using λ-DNA as a template. It also relates to a DNA polymerase-constituting protein; a DNA containing the base sequence encoding thereof; and a method for producing the DNA polymerase. The present invention provides a novel DNA polymerase possessing both a high primer extensibility and a 3'→5' exonuclease activity.

EP 0 870 832 A1

**Description****TECHNICAL FIELD**

5 The present invention relates a DNA polymerase which is useful for a reagent for genetic engineering, a method for producing the same, and a gene encoding thereof.

**BACKGROUND ART**

10 DNA polymerases are useful enzymes for reagents for genetic engineering, and the DNA polymerases are widely used for a method for determining a base sequence of DNA, labeling, a method of site-directed mutagenesis, and the like. Also, thermostable DNA polymerases have recently been remarked with the development of the polymerase chain reaction (PCR) method, and various DNA polymerases suitable for the PCR method have been developed and commercialized.

15 Presently known DNA polymerases can be roughly classified into four families according to amino acid sequence homologies, among which family A (pol I type enzymes) and family B ( $\alpha$  type enzymes) account for the great majority. Although DNA polymerases belonging to each family generally possess mutually similar biochemical properties, detailed comparison reveals that individual DNA polymerase enzymes differ from each other in terms of substrate specificity, substrate analog incorporation, degree and rate for primer extension, mode of DNA synthesis, association of  
20 exonuclease activity, optimum reaction conditions of temperature, pH and the like, and sensitivity to inhibitors. Thus, those possessing especially suitable properties for the respective experimental procedures have been selectively used of all available DNA polymerases.

**DISCLOSURE OF INVENTION**

25 An object of the present invention is to provide a novel DNA polymerase not belonging to any of the above families, and possessing biochemical properties not owned by any of the existing DNA polymerases. For example, primer extension activity and 3'→5' exonuclease activity are considered as mutually opposite properties, and none of the existing DNA polymerase enzymes with strong primer extension activity possess 3'→5' exonuclease activity, which is an important proofreading function for DNA synthesis accuracy. Also, the existing DNA polymerases possessing excellent proof-  
30 reading functions are poor in primer extension activity. Therefore, development of a DNA polymerase possessing both potent primer extension activity and potent 3'→5' exonuclease activity would significantly contribute to DNA synthesis *in vitro*.

35 Another object of the present invention is to provide a method for producing the novel DNA polymerase mentioned above.

A still another object of the present invention is to provide a gene encoding the DNA polymerase of the present invention.

40 As a result of extensive investigation, the present inventors have found genes of the novel DNA polymerase from hyperthermophilic archaeobacterium *Pyrrococcus furiosus*, followed by cloning of the above genes, and have clarified that two kinds of novel proteins possess a novel DNA polymerase activity exhibiting the activity under coexistence of the above two kinds of proteins. Furthermore, the present inventors have prepared a transformant into which the above genes are introduced, and have succeeded in mass-producing the complex type DNA polymerase.

Accordingly, the gist of the present invention is as follows:

45 [1] A DNA polymerase characterized in that the DNA polymerase possesses the following properties:

1) exhibiting higher polymerase activity when assayed by using as a substrate a complex resulting from primer annealing to a single stranded template DNA, as compared to the case where an activated DNA is used as a substrate;

50 2) possessing a 3'→5' exonuclease activity;

3) being capable of amplifying a DNA fragment of about 20 kbp, in the case where polymerase chain reaction (PCR) is carried out using  $\lambda$ -DNA as a template under the following conditions:

PCR conditions:

55 (a) a composition of reaction mixture: containing 10 mM Tris-HCl (pH 9.2), 3.5 mM MgCl<sub>2</sub>, 75 mM KCl, 400  $\mu$ M each of dATP, dCTP, dGTP and dTTP, 0.01% bovine serum albumin, 0.1% Triton X-100, 5.0 ng/50  $\mu$ l  $\lambda$ -DNA, 10 pmole/50  $\mu$ l primer  $\lambda$ 1 (SEQ ID NO:8 in Sequence Listing), primer  $\lambda$ 11 (SEQ ID NO:9 in Sequence Listing),

and 3.7 units/50  $\mu$ l DNA polymerase;

(b) reaction conditions: carrying out a 30-cycle PCR, wherein one cycle is defined as at 98°C for 10 seconds and at 68°C for 10 minutes;

- 5 [2] The DNA polymerase according to the above item [1], characterized in that the DNA polymerase exhibits a lower error rate in DNA synthesis as compared to Taq DNA polymerase;
- [3] The DNA polymerase according to the above item [1] or [2], wherein the molecular weight as determined by gel filtration method is about 220 kDa or about 385 kDa;
- 10 [4] The DNA polymerase according to any one of the above items [1] to [3], characterized in that the DNA polymerase exhibits an activity under coexistence of two kinds of DNA polymerase-constituting protein, a first DNA polymerase-constituting protein and a second DNA polymerase-constituting protein;
- [5] The DNA polymerase according to the above item [4], characterized in that the molecular weights of the first DNA polymerase-constituting protein and the second DNA polymerase-constituting protein are about 90,000 Da and about 140,000 Da as determined by SDS-PAGE, respectively;
- 15 [6] The DNA polymerase according to the above item [4] or [5], characterized in that the first DNA polymerase-constituting protein which constitutes the DNA polymerase according to the above item [4] or [5] comprises the amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence;
- 20 [7] The DNA polymerase according to the above item [4] or [5], characterized in that the second DNA polymerase-constituting protein which constitutes the DNA polymerase according to the above item [4] or [5] comprises the amino acid sequence as shown by SEQ ID NO:3 in sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence;
- 25 [8] The DNA polymerase according to item [4] or [5], characterized in that the first DNA polymerase-constituting protein which constitutes the DNA polymerase according to the above item [4] or [5] comprises the amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence, and that the second DNA polymerase-constituting protein which constitutes the DNA
- 30 polymerase according to the above item [4] or [5] comprises the amino acid sequence as shown by SEQ ID NO:3 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence;
- [9] A first DNA polymerase-constituting protein which constitutes the DNA polymerase according to the above item [4] or [5], wherein the first DNA polymerase-constituting protein comprises the amino acid sequence as shown by
- 35 SEQ ID NO:1, or an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence, as a functional equivalent thereof possessing substantially the same activity;
- [10] A second DNA polymerase-constituting protein which constitutes the DNA polymerase according to the above [4] or [5], wherein the second DNA polymerase-constituting protein comprises the amino acid sequence as shown
- 40 by SEQ ID NO:3, or an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence as a functional equivalent thereof possessing substantially the same activity;
- [11] A DNA containing a base sequence encoding the first DNA polymerase-constituting protein according to the above item [9], characterized in that the DNA comprises an entire sequence of a base sequence encoding the
- 45 amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing, or a partial sequence thereof, or that the DNA encodes a protein having an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence of SEQ ID NO:1 and possessing a function as the first DNA polymerase-constituting protein;
- [12] A DNA containing a base sequence encoding the first DNA polymerase-constituting protein according to the above items [9], characterized in that the DNA comprises an entire sequence of the base sequence as shown by
- 50 SEQ ID NO:2 in Sequence Listing or a partial sequence thereof, or that the DNA comprises a base sequence capable of hybridizing thereto under stringent conditions;
- [13] A DNA containing a base sequence encoding the second DNA polymerase-constituting protein according to the above item [10], characterized in that the DNA comprises an entire sequence of a base sequence encoding the
- 55 amino acid sequence as shown by SEQ ID NO:3, or a partial sequence thereof, or that the DNA encodes a protein having an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence of SEQ ID NO:3 and possessing a function as the second DNA polymerase-constituting protein;

[14] A DNA containing a base sequence encoding the second DNA polymerase-constituting protein according to the item [10], characterized in that the DNA comprises an entire sequence of the base sequence as shown by SEQ ID NO:4 in Sequence Listing or a partial sequence thereof, or that the DNA comprises a base sequence capable of hybridizing thereto under stringent conditions;

[15] A method for producing a DNA polymerase, characterized in that the method comprises culturing a transformant containing both gene encoding the first DNA polymerase-constituting protein according to the above item [11] or [12], and gene encoding the second DNA polymerase-constituting protein according to the above item [13] or [14], and collecting the DNA polymerase from the resulting culture; and

[16] A method for producing a DNA polymerase, characterized in that the method comprises culturing a transformant containing gene encoding the first DNA polymerase-constituting protein according to the above item [11] or [12], and a transformant containing gene encoding the second DNA polymerase-constituting protein according to the above item [13] or [14], separately; mixing DNA polymerase-constituting proteins contained in the resulting culture; and collecting the DNA polymerase.

#### BRIEF DESCRIPTION OF DRAWINGS

Figure 1 shows a restriction endonuclease map of the DNA fragment inserted into the cosmid Clone No. 264 and the cosmid Clone No. 491 obtained in Example 1.

Figure 2 shows a restriction endonuclease map of an *Xba*I-*Xba*I DNA fragment inserted into a plasmid pFU1001.

Figure 3 is a graph for an optimum pH of the DNA polymerase of the present invention.

Figure 4 is a graph for a heat stability of the DNA polymerase of the present invention.

Figure 5 is a graph for a 3'→5' exonuclease activity of the DNA polymerase of the present invention.

Figure 6 is an autoradiogram for a primer extension activity of the DNA polymerase of the present invention.

#### BEST MODE FOR CARRYING OUT THE INVENTION

##### (1) DNA Polymerase of Present Invention and Constituting Proteins Thereof

An example of the DNA polymerase of the present invention has the following properties:

- 1) exhibiting higher polymerase activity when assayed by using as a substrate a complex resulting from primer annealing to a single stranded template DNA, as compared to the case where an activated DNA (DNase I-treated calf thymus DNA) is used as a substrate;
- 2) possessing a 3'→5' exonuclease activity;
- 3) optimum pH being between 6.5 and 7.0 (in potassium phosphate buffer, at 75°C);
- 4) exhibiting a remaining activity of about 80% after heat treatment at 80°C for 30 minutes;
- 5) being capable of amplifying a DNA fragment of about 20 kbp, in the case where polymerase chain reaction (PCR) is carried out using  $\lambda$ -DNA as a template under the following conditions:

PCR conditions:

(a) composition of reaction mixture: containing 10 mM Tris-HCl (pH 9.2), 3.5 mM MgCl<sub>2</sub>, 75 mM KCl, 400  $\mu$ M each of dATP, dCTP, dGTP and dTTP, 0.01% bovine serum albumin (BSA), 0.1% Triton X-100, 5.0 ng/50  $\mu$ l  $\lambda$ -DNA, 10 pmole/50  $\mu$ l primer  $\lambda$ 1 (SEQ ID NO:8 in Sequence Listing), primer  $\lambda$ 11 (SEQ ID NO:9 in Sequence Listing), and 3.7 units/50  $\mu$ l DNA polymerase. Here, one unit of the DNA polymerase is defined as follows: Fifty microliters of a reaction mixture [20 mM Tris-HCl (pH 7.7), 15 mM MgCl<sub>2</sub>, 2 mM 2-mercaptoethanol, 0.2 mg/ml activated DNA, 40  $\mu$ M each of dATP, dCTP, dGTP and dTTP, 60 nM [<sup>3</sup>H]-dTTP (manufactured by Amersham)], containing a sample to assay activity, is reacted at 75°C for 15 minutes. A 40  $\mu$ l portion of this reaction mixture is spotted onto a DE paper (manufactured by Whatman) and washed with 5% Na<sub>2</sub>HPO<sub>4</sub> five times. Thereafter, the remaining radioactivity on the DE paper is measured using a liquid scintillation counter, and the amount of the enzyme causing the incorporation of 10 nmol of [<sup>3</sup>H]-dTTP per 30 minutes into a substrate DNA is defined as one unit of the enzyme; and

(b) PCR conditions: carrying out a 30-cycle PCR, wherein one cycle is defined as at 98°C for 10 seconds and at 68°C for 10 minutes; and

6) The DNA polymerase of the present invention is superior to the Taq DNA polymerase in terms of both primer extension activity and accuracy of DNA synthesis. Specifically, the DNA polymerase of the present invention is superior to the Taq DNA polymerase, a typical thermostable DNA polymerase (e.g., TaKaRa Taq, manufactured by Takara Shuzo Co., Ltd.), in terms of primer extension properties in DNA synthesis reaction, for instance, DNA

strand length capable of DNA amplification by PCR method, and accuracy of DNA synthesis reaction (low error rate in DNA synthesis).

The DNA polymerase of the present invention is an enzyme constituted by two kinds of proteins, wherein a molecular weight of the DNA polymerase of the present invention is about 220 kDa or about 385 kDa, as determined by gel filtration, and also shown by two bands corresponding to about 90,000 Da and about 140,000 Da on SDS-PAGE, respectively. The protein of about 90,000 Da (corresponding to ORF3 as described below) is herein referred to as the first DNA polymerase-constituting protein, and the protein of about 140,000 Da (corresponding to ORF4 as described below) is herein referred to as the second DNA polymerase-constituting protein. It is assumed that in the DNA polymerase of the present invention, the first DNA polymerase-constituting protein and the second DNA polymerase-constituting protein are non-covalently bonded to form a complex in a molar ratio of 1:1 or 1:2.

The first DNA polymerase-constituting protein which constitutes the DNA polymerase of the present invention may comprise the amino acid sequence shown by SEQ ID NO:1 in Sequence Listing, or may be a functional equivalent possessing substantially the same activity. Also, the second DNA polymerase-constituting protein may comprise the amino acid sequence shown by SEQ ID NO:3 in Sequence Listing, or may be a functional equivalent possessing substantially the same activity.

The term "a functional equivalent" as described in the present specification is defined as follows. A protein existing in nature can undergo mutation, such as deletion, insertion, addition and substitution, of amino acids in an amino acid sequence thereof owing to modification reaction and the like of the protein itself *in vivo* or during purification, besides causation such as polymorphism and mutation of the genes encoding it. However, it has been known that there are some proteins which exhibit substantially the same physiological activities or biological activities as a protein without mutation. Those proteins having structural differences as described above without recognizing any significant differences of the functions and the activities thereof, are referred to as "a functional equivalent." Here, the number of mutated amino acids is not particularly limited, as long as the resulting protein exhibits substantially the same physiological activities or biological activities as a protein without mutation. Examples thereof include one or more of mutations, for instance, one or several mutations, more specifically one to about ten mutations (such as deletion, insertion, addition and substitution) and the like.

The same can be said for the resulting proteins in the case where the above mutation is artificially introduced into the amino acid sequence of a protein. In this case, more diverse mutants can be prepared. For example, although the methionine residue at the N-terminus of a protein expressed in *Escherichia coli* is reportedly often removed by the action of methionine aminopeptidase, since the methionine residue is not removed perfectly depending on the kinds of proteins, those having methionine residue and those without methionine residue can be both produced. However, the presence or absence of the methionine residue does not affect protein activity in most cases. It is also known that a polypeptide resulting from substitution of a particular cysteine residue with serine in the amino acid sequence of human interleukin 2 (IL-2) retains IL-2 activity [Science, 224, 1431 (1984)].

In addition, during the production of a protein by genetic engineering, the desired protein is often expressed as a fusion protein. For example, purification of the desired protein is facilitated by adding the N-terminal peptide chain derived from another protein to the N-terminus of the desired protein to increase the amount of expression of the desired protein, or by adding an appropriate peptide chain to the N- or C-terminus of the desired protein, expressing the protein, and using a carrier having affinity for the peptide chain added. Accordingly, a DNA polymerase having an amino acid sequence which has a partial difference with that of the DNA polymerase of the present invention is within the scope of the present invention as "a functional equivalent," as long as it exhibits substantially the same activities as the DNA polymerase of the present invention.

## (2) Gene of DNA Polymerase of Present Invention

The DNA encoding the first DNA polymerase-constituting protein which constitutes the DNA polymerase of the present invention includes a DNA comprising an entire sequence of the base sequence encoding the amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing or a partial sequence thereof including, for instance, a DNA comprising an entire sequence of the base sequence as shown by SEQ ID NO:2 or a partial sequence thereof. Specifically, a DNA comprising a partial sequence of the base sequence encoding the amino acid sequence as shown by SEQ ID NO:1 including, for instance, the DNA comprising a partial sequence of the base sequence as shown by SEQ ID NO:2 in Sequence Listing, the base sequence encoding a protein possessing a function of the first DNA polymerase-constituting protein is also included in the scope of the present invention. Also, in the amino acid sequence as shown by SEQ ID NO:1, the above DNA also includes a DNA encoding a protein comprising an amino acid sequence resulting from deletion, insertion, addition, substitution and the like of one or several amino acids, the protein possessing a function of the first DNA polymerase-constituting protein. Furthermore, a base sequence capable of hybridizing to the above base sequences under the stringent conditions, the base sequence encoding a protein possessing a function of the first

DNA polymerase-constituting protein, is also included in the scope of the present invention. In addition, the DNA encoding the second DNA polymerase-constituting protein which constitutes the DNA polymerase of the present invention includes a DNA comprising an entire sequence of the base sequence encoding the amino acid sequence as shown by SEQ ID NO:3 in Sequence Listing or a partial sequence thereof including, for instance, a DNA comprising an entire sequence of the base sequence as shown by SEQ ID NO:4 in Sequence Listing or a partial sequence thereof. Specifically, the DNA comprising a partial sequence of the base sequence encoding the amino acid sequence as shown by SEQ ID NO:3, for instance, the DNA comprising a partial sequence of the base sequence as shown by SEQ ID NO:4 in Sequence Listing, the base sequence encoding a protein possessing a function of the second DNA polymerase-constituting protein, is also included in the scope of the present invention. Also, in the amino acid sequence as shown by SEQ ID NO:3, the above DNA also includes a DNA encoding a protein comprising an amino acid sequence resulting from deletion, insertion, addition, substitution and the like of one or several amino acids, the protein possessing a function of the second DNA polymerase-constituting protein. Furthermore, a base sequence capable of hybridizing to the above base sequences under the stringent conditions, the base sequence encoding a protein possessing a function of the second DNA polymerase-constituting protein, is also included in the scope of the present invention.

The term "protein possessing a function of the first DNA polymerase-constituting protein" or "protein possessing a function of the second DNA polymerase-constituting protein" herein refers to a protein possessing properties exhibiting a DNA polymerase activity with various physicochemical properties shown in the above items 1) to 6).

Here, the term "capable of hybridizing under the stringent conditions" refer to hybridizing to a probe, after incubating at 50°C for 12 to 20 hours in  $6 \times$  SSC (wherein  $1 \times$  SSC shows 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0) containing 0.5% SDS, 0.1% bovine serum albumin (BSA), 0.1% polyvinyl pyrrolidone, 0.1% Ficol 400, and 0.01% denatured salmon sperm DNA with the probe.

The term "DNA containing a base sequence encoding an amino acid sequence" described in the present specification will be explained. One to six kinds are known to exist for each amino acid with regards to a codon (triplet base combination) for designating a particular amino acid on the gene. Therefore, there can be a large number of DNA encoding an amino acid sequence, though depending on the amino acid sequence. In nature, genes do not always exist in stable forms, and it is not rare for genes to undergo mutations on a base sequence. There may be a case where mutations on the base sequence do not give rise to any changes in an amino acid sequence to be encoded (referred to as silent mutation). In this case, it can be said that different kinds of genes encoding the same amino acid sequence have been generated. The possibility, therefore, cannot be negated for producing a variety of genes encoding the same amino acid sequence after many generations of the organism even when a gene encoding a particular amino acid sequence is isolated.

Moreover, it is not difficult to artificially produce a variety of genes encoding the same amino acid sequence by means of various genetic engineering techniques. For example, when a codon used in the natural gene encoding the desired protein is used at a low frequency in the host in the production of the protein by genetic engineering, the amount of a protein expressed is sometimes low. In this case, high expression of the desired protein is achieved by artificially converting the codon into another one used at a high frequency in the host without changing the amino acid sequence encoded (for instance, Japanese Patent Laid-Open No. Hei 7-102146). As described above, it is, of course, possible to artificially produce a variety of genes encoding a particular amino acid sequence. Such artificially produced different polynucleotides are, therefore, included in the scope of the present invention, as long as the gene encodes the amino acid sequence disclosed in the present invention.

### (3) Method for Producing DNA Polymerase of Present Invention

The present inventors have found genes of a novel DNA polymerase from a hyperthermophilic archaeobacterium, *Pyrococcus furiosus*, and cloned to clarify that the genes encode a novel DNA polymerase exhibiting its activity by the coexistence of two kinds of proteins on the genes. In the present invention, the DNA polymerase of the present invention can be mass-produced by preparing transformants incorporating the above genes. For this purpose, the transformant may be prepared by a process comprising culturing a transformant containing both the gene encoding the first DNA polymerase-constituting protein and the gene encoding the second DNA polymerase-constituting protein, and collecting the DNA polymerase from the resulting culture. Alternatively, the transformant may be prepared by a process comprising separately culturing a transformant containing the gene encoding the first DNA polymerase-constituting protein and a transformant containing the gene encoding the second DNA polymerase-constituting protein, mixing the DNA polymerase-constituting proteins contained in the resulting culture, and collecting the DNA polymerase therefrom.

Here, the phrase "transformant containing both the gene encoding the first DNA polymerase-constituting protein and the gene encoding the second DNA polymerase-constituting protein" may be a transformant resulting from co-transformation with two expression vectors containing the respective genes, or it may be a transformant prepared by recombining both genes into one expression vector to allow the respective proteins to be expressed.

(4) A cloning of the genes of the DNA polymerase of the present invention, an analysis of obtained clones, physico-chemical properties, activities, applicabilities to PCR method of expression product DNA polymerase, and the like are hereinafter described in detail.

5 The strain used for the present invention is not subject to particular limitation. Examples thereof include *Pyrococcus furiosus* DSM3638, as a strain belonging to the genus *Pyrococcus*. The above strain can be made available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. In the case of culturing the above strain in an appropriate growth culture, preparing a crude extract from the resulting culture, and subjecting the crude extract to a polyacrylamide gel electrophoresis, since the present inventors found existences of several kinds of protein bands  
10 showing DNA polymerase activity in the gel, it has been anticipated that the genes corresponding to these respective bands have existed. Specifically, the novel DNA polymerase gene and the product thereof can be cloned by the procedures exemplified below.

- 1) DNA is extracted from *Pyrococcus furiosus*;
- 15 2) The DNA obtained in 1) is digested with an appropriate restriction endonuclease, to prepare a DNA library with a plasmid, cosmid and the like, as a vector;
- 3) The library prepared in 2) is introduced into *Escherichia coli*, and a foreign gene is expressed to prepare a protein library in which crude extracts of the resulting clones are collected;
- 4) A DNA polymerase activity is assayed by using the protein library prepared in 3), and a foreign DNA is taken out  
20 from the *Escherichia coli* clone which provides a crude extract having an activity;
- 5) The *Pyrococcus furiosus* DNA fragment contained in the plasmid or cosmid taken out is analyzed to narrow down the gene region encoding a protein exhibiting a DNA polymerase activity;
- 6) The base sequence of the region in which the protein exhibiting a DNA polymerase activity is presumably encoded is determined to deduce the primary structure of the protein; and
- 25 7) An expression plasmid is constructed to take a form which more easily allows the expression of the protein deduced in 6) in *Escherichia coli*, and the produced protein is purified and analyzed for the properties thereof.

The above DNA donor, *Pyrococcus furiosus* DSM3638, is a hyperthermophilic archaeobacterium, which is cultured at 95°C under anaerobic conditions. Known methods can be used as a method for disrupting grown cells followed by  
30 extracting and purifying DNA, a method for digesting the obtained DNA with a restriction endonuclease and for other methods. Such methods are described in detail by in *Molecular Cloning: A Laboratory Manual*, 75-178, published by Cold Spring Harbor Laboratory in 1982, edited by T. Maniatis et al.

In the preparation of a DNA library, the triple helix cosmid vector (manufactured by Stratagene), for example, can be used. The DNA of *Pyrococcus furiosus* is partially digested with *Sau3AI* (manufactured by Takara Shuzo Co., Ltd.),  
35 and the digested DNA is subjected to density gradient centrifugation to obtain the long DNA fragments. They are ligated to the *Bam*HI site of the above vector, followed by *in vitro* packaging. The respective transformants obtained from the DNA library thus prepared are separately cultured. After harvesting, cells are disrupted by ultrasonication, and the resulting disruption is heat-treated to inactivate the DNA polymerase from the host *Escherichia coli*. Thereafter, a supernatant containing a thermostable protein can be obtained by centrifugation. The above supernatant is named as  
40 a cosmid protein library. By means of assaying the DNA polymerase activity using a portion of the supernatant, a clone that expresses the DNA polymerase derived from *Pyrococcus furiosus* can be obtained. DNA polymerase activity can be assayed using the known method described in *DNA Polymerase from Escherichia coli*, published by Harper and Row, edited by D.R. Davis, 263-276 (authored by C.C. Richardson).

One of the DNA polymerase genes of *Pyrococcus furiosus* has already been cloned and its structure clarified by  
45 the present inventors, as described in *Nucleic Acids Research*, 21, 259-265 (1993). The translation product of the above gene is a polypeptide having a molecular weight of about 90,000 Da and consisting of 775 amino acids, and the amino acid sequence thereof clearly contains preserved sequences of the  $\alpha$ -type DNA polymerases. In fact, since the DNA polymerase activity exhibited by this gene product is inhibited by aphidicolin, which is a specific inhibitor of  $\alpha$ -type DNA polymerases, the above DNA polymerase is distinguishable from the DNA polymerase of the present invention.  
50 Therefore, the above known gene out of the obtained clones exhibiting thermostable DNA polymerase activity can be removed by a process comprising digesting the cosmid contained in each clone, carrying out hybridization with the above gene as a probe, and selecting an unhybridizing clone. A restriction endonuclease map of the DNA insert can be prepared for the cosmid digested with the resulting clone containing the novel DNA polymerase gene. Next, a location of the DNA polymerase gene on the above DNA fragment can be determined by a process comprising dividing the  
55 above DNA fragment into various regions on the basis of the obtained restriction endonuclease map, subcloning each region into a plasmid vector, introducing the resulting vector into *Escherichia coli*, and assaying the thermostable DNA polymerase activity exhibited therein. An *Xba*I-*Xba*I DNA fragment of about 10 kbp containing the DNA polymerase gene can be thus obtained.

The recombinant *Escherichia coli* harboring a plasmid incorporating the above DNA fragment exhibits a sufficient level of a DNA synthesis activity in the crude extract thereof even after treatment at 90°C for 20 minutes, while such an activity is not found in any plasmids without incorporating a DNA fragment. Therefore, it can be concluded that the information for producing a thermostable polymerase is present on the DNA fragment, and that a gene having the above information is expressed in the above *Escherichia coli*. The plasmid resulting from recombination of the DNA fragment into a pTV118N vector (manufactured by Takara Shuzo Co., Ltd.) is named as pFU1001. The *Escherichia coli* JM109 transformed with the above plasmid is named and identified as *Escherichia coli* JM109/pFU1001, has been deposited under accession number FERM BP-5579 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, of which the address is 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, 305, Japan, since August 11, 1995 (date of original deposit) under the Budapest Treaty.

The base sequence of the DNA fragment inserted in the plasmid pFU1001 can be determined by a conventional method, for instance, by the dideoxy method. Furthermore, regions capable of encoding a protein in the base sequence, i.e., open reading frames (ORFs), can be deduced by analyzing the resulting base sequence.

An 8,450 bp sequence in the base sequence of the *Xba*I-*Xba*I DNA fragment of about 10 kbp inserted in the plasmid pFU1001 is shown by SEQ ID NO:5 in Sequence Listing. In the base sequence, there are six consecutive ORFs, named as ORF1, ORF2, ORF3, ORF4, ORF5, and ORF6, respectively, naming from the 5' terminal side. FIG. 2 shows the restriction endonuclease map of the above *Xba*I-*Xba*I fragment and the location of the ORFs on the fragment (ORF1 to ORF6, from the left in the Figure).

A sequence showing homologies to any of known DNA polymerases was not found in any one of the above six ORFs. It should be noted, however, that on ORF1 and ORF2, there is a sequence homologous to the CDC6 protein found in *Saccharomyces cerevisiae*, or a sequence homologous to the CDC18 protein found in *Schizosaccharomyces pombe*. The CDC6 and the CDC18 are anticipated as proteins that are necessary for the cell cycle shift to the DNA synthesis phase (S phase) in yeasts, the proteins regulating initiation of the DNA replication. Also, the ORF6 has a sequence homologous to the RAD51 protein, known to act in DNA damage repair in yeasts and recombination in the somatic mitosis phase and in the meiosis phase in yeasts, and a sequence homologous to the Dmc1 protein, a meiosis phase-specific homolog to the RAD51 protein. The gene encoding the RAD51 protein is also known to be expressed at the cell cycle shift from the G1 to S phase. For the other ORFs, namely ORF3, ORF4, and ORF5, there have been no known proteins found to have a homologous sequence.

It is possible to determine from which of the above ORFs the thermostable DNA polymerase activity is derived by a process comprising preparing recombinant plasmids inserted with the respective DNA fragments deleting various regions, transforming a host with the plasmids, and assaying the thermostable polymerase activity of each transformant obtained. The transformant resulting from transformation with a recombinant plasmid inserted with a DNA fragment prepared by deleting ORF1 or ORF2, or deleting ORF5 or ORF6, from the above *Xba*I-*Xba*I DNA fragment of about 10 kbp retains the thermostable DNA polymerase activity, while those resulting from transformation with a recombinant plasmid inserted with a DNA fragment prepared by deleting ORF3 or ORF4 loses its activity. This fact predicts that the DNA polymerase activity is encoded by ORF3 or ORF4.

It is possible to determine by which of ORF3 and ORF4 the DNA polymerase is encoded by a process comprising preparing recombinant plasmids separately inserted with the respective ORFs, transforming a host with each recombinant plasmid, and assaying exhibition of a thermostable DNA polymerase activity in each transformant obtained. Unexpectedly, only very weak DNA polymerase activity is detected in a crude extract obtained from the transformant containing ORF3 or ORF4 alone. However, since a similar level of a thermostable DNA polymerase activity to that in the transformant containing both ORF3 and ORF4 can be obtained in the case where the two extracts are mixed, it is shown that the novel DNA polymerase of the present invention requires the actions of the translation products of the two ORFs. It is possible to find out whether the two proteins form a complex to exhibit the DNA polymerase activity, or one modifies the other to convert it to an active enzyme by determining the molecular weight of the DNA polymerase. The results of the determination of the molecular weight of the above DNA polymerase by gel filtration method demonstrate that the above two proteins form a complex.

The base sequence of ORF3 is shown by SEQ ID NO:2 in Sequence Listing, and the amino acid sequence of the ORF3-derived translation product, namely the first DNA polymerase-constituting protein as deduced from the base sequence, is shown by SEQ ID NO:1. The base sequence of ORF4 is shown by SEQ ID NO:4 in Sequence Listing, and the amino acid sequence of the ORF4-derived translation product, namely the second DNA polymerase-constituting protein as deduced from the base sequence, is shown by SEQ ID NO:3.

The DNA polymerase of the present invention can be expressed in cells by culturing a transformant resulting from transformation with a recombinant plasmid into which both ORF3 and ORF4 are introduced, for instance, *Escherichia coli* JM109/pFU1001, under usual culturing conditions, for instance, culturing in an LB medium (10 g/l trypton, 5 g/l yeast extract, 5 g/l NaCl, pH 7.2) containing 100 µg/ml ampicillin. The above polymerase can be purified from the above cultured cells to the extent that only the two kinds of bands of nearly two kinds of the DNA polymerase-constituting pro-



teins are obtained in SDS-polyacrylamide gel electrophoresis (SDS-PAGE), by carrying out ultrasonication, heat treatment, and chromatography using an anionic exchange column (RESOURCE Q column, manufactured by Pharmacia), a heparin Sepharose column (HiTrap Heparin, manufactured by Pharmacia), a gel filtration column (Superose 6HR, manufactured by Pharmacia) or the like. It is also possible to obtain the desired DNA polymerase by a process comprising separately culturing transformants respectively containing ORF3 or ORF4 alone as described above, and subsequently mixing the cultured cells obtained, their crude extracts, or purified DNA polymerase-constituting proteins. When mixing the two kinds of DNA polymerase-constituting proteins, special procedures are not required, and the DNA polymerase possessing an activity can be obtained simply by mixing the extracts from the respective transformants or the two proteins purified therefrom in appropriate amounts.

The DNA polymerase of the present invention thus obtained provides two bands at positions corresponding to molecular weights of about 90,000 Da and about 140,000 Da on the SDS-PAGE, and these two bands corresponding to the first and second DNA polymerase-constituting proteins, respectively.

As shown in FIG. 3, the DNA polymerase of the present invention exhibits the optimum pH is in the neighborhood of 6.5 to 7.0 at 75°C in a potassium phosphate buffer. When an enzyme activity of the above DNA polymerase is assayed at various temperatures, the enzyme exhibits a high activity at 75° to 80°C. However, because the double stranded structure of the activated DNA used as a substrate for activity assay is destructed at higher temperatures, an accurate optimum temperature for the activity of the above enzyme has not been assayed. The above DNA polymerase possesses a high heat stability, retaining not less than 80% of the remaining activity even after a heat treatment at 80°C for 30 minutes, as shown in FIG. 4. This level of the heat stability allows the use of the above enzyme for PCR method. Also, when assessing the influence of aphidicolin, a specific inhibitor of  $\alpha$ -type DNA polymerases, it is demonstrated that the activity of the above DNA polymerase is not inhibited even in the presence of 2 mM aphidicolin.

As a result of analyzing the biochemical properties of the purified DNA polymerase, the DNA polymerase of the present invention possesses very excellent primer extension activity *in vitro*. As shown in Table 1, in the case where DNA polymerase activity is assayed using a substrate in a form resulting from primer annealing to a single stranded DNA (the M13-HT Primer), higher nucleotide incorporating activity as compared to that of the activated DNA used for usual activity assaying (DNase I-treated calf thymus DNA) can be demonstrated. When the primer extension ability of the DNA polymerase of the present invention is compared with that of other DNA polymerases using the above M13-HT Primer substrate, the DNA polymerase of the present invention exhibits superior extension activity as compared to known DNA polymerases derived from *Pyrococcus furiosus* (Pfu DNA polymerase, manufactured by Stratagene) and Taq DNA polymerase derived from *Thermus aquaticus* (Taq DNA polymerase, manufactured by Takara Shuzo Co., Ltd.). Furthermore, when an activated DNA is added to this reaction system as a competitor substrate, the primer extension activities of the above two kinds of DNA polymerases are strongly inhibited, while that of the DNA polymerase of the present invention is inhibited at a low level, demonstrating that the DNA polymerase of the present invention possesses a high affinity for substrates of the primer extension type (FIG. 6).

Table 1

| Substrates            | Relative Activity                       |                    |                    |
|-----------------------|---|--------------------|--------------------|
|                       | DNA Polymerase of the Present Invention | Pfu DNA Polymerase | Taq DNA Polymerase |
| activated DNA         | 100                                     | 100                | 100                |
| thermal-denatured DNA | 340                                     | 87                 | 130                |
| M13-HT primer         | 170                                     | 23                 | 90                 |
| M13-RNA primer        | 52                                      | 0.49               | 38                 |
| poly dA-Oligo dT      | 94                                      | 390                | 290                |
| poly A-Oligo dT       | 0.085                                   | -                  | 0.063              |

Also, the DNA polymerase of the present invention shows excellent performance when used for the PCR method. In the DNA polymerase derived from *Thermus aquaticus*, commonly used for the PCR method, it is difficult to amplify a DNA fragment of not less than 10 kbp using, the above DNA polymerase alone, and a DNA fragment of not less than 20 kbp can be amplified when used in combination with another DNA polymerase [Proceedings of the National Academy of Sciences of the USA, 91, 2216-2220 (1994)]. Also, the strand length of DNA amplifiable using the Pfu DNA polymerase is reportedly at most about 3 kbp. By contrast, when using the DNA polymerase of the present invention, the amplification of a DNA fragment of 20 kbp in length is made possible even when used alone without addition of any

other enzymes.

Moreover, the DNA polymerase of the present invention which also has associated 3'→5' exonuclease activity is comparable to the Pfu DNA polymerase, known to ensure very high accuracy in DNA synthesis, owing to its high activity in terms of the ratio of the exonuclease activity to the DNA polymerase activity (FIG. 5). Also, the error rate during the DNA synthesis reaction is lower for the DNA polymerase of the present invention than that of the Taq DNA polymerase. The various properties demonstrate that the DNA polymerase of the present invention serves very excellently as a reagent for genetic engineering techniques such as the PCR method.

The finding of the novel DNA polymerase genes according to the present invention also provides an interesting suggestion as follows. In order to determine the manner in which the region containing the genes for ORF3 and ORF4 encoding a novel DNA polymerase is intracellularly transcribed, the present inventors have analyzed an RNA fraction prepared from *Pyrococcus furiosus* cells by northern blotting method, RT-PCR method and primer extension method. As a result, it is confirmed that ORF1 to ORF6 are transcribed from immediately upstream of ORF1 as a single messenger RNA (mRNA). From the above finding, there is an expectation that the production of the ORF1 and the ORF2 in cells is subjected to the same control as that for the ORF3 and the ORF4. When considering in combination with the sequence homologies of ORF1, ORF2, ORF5, and ORF6 to those of CDC6 and CDC18, the CDC6 and the CDC18 being involved in the regulation for initiation of the DNA replication in yeasts, the above expectation suggests that the novel DNA polymerase of the present invention is highly likely to be a DNA polymerase important for the DNA replication. Since it is also expected that the DNA replication system of archaeobacteria, to which group *Pyrococcus furiosus* belongs, is closely related to that of eukaryotic cells, there is a possibility of the presence of an enzyme similar to the DNA polymerase of the present invention as a DNA polymerase important for replication that has not been found in eukaryotes.

It is also expected that thermostable DNA polymerases similar to the DNA polymerase of the present invention are produced in other bacteria belonging to hyperthermophilic archaeobacteria like *Pyrococcus furiosus*, including, for instance, bacteria other than *Pyrococcus furiosus* belonging to the genus *Pyrococcus*; bacteria belonging to the genus *Pyrodictium*; the genus *Thermococcus*, the genus *Staphylothermus*, and other genera. When these enzymes are constituted by two DNA polymerase-constituting proteins, like the DNA polymerase of the present invention, it is expected that a similar DNA polymerase activity is exhibited by combining one of the two DNA polymerase-constituting proteins and the DNA polymerase-constituting protein of the present invention corresponding to the other DNA polymerase-constituting protein.

The thermostable DNA polymerases similar to the DNA polymerase of the present invention, produced by the above hyperthermophilic archaeobacteria, are expected to have homology to the DNA polymerase of the present invention in terms of its amino acid sequence and the base sequence of the gene encoding thereof. It is therefore possible to obtain the gene for a thermostable DNA polymerase similar to the DNA polymerase of the present invention of which the base sequence is not identical to that of the DNA polymerase of the present invention but possesses similar enzyme activities by a process comprising introducing into an appropriate microorganism a DNA fragment obtained from one of the above thermophilic archaeobacteria by hybridization using, as a probe, a gene isolated by the present invention or a portion of the above base sequence, and assaying the DNA polymerase activity in a heat-treated lysate prepared in the same manner as the above cosmid protein library by an appropriate method.

The above hybridization can be carried out under the following conditions. Specifically, a DNA-immobilized membrane is incubated with a probe at 50°C for 12 to 20 hours in 6 x SSC, wherein 1 x SSC indicates 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0, containing 0.5% SDS, 0.1% bovine serum albumin, 0.1% polyvinyl pyrrolidone, 0.1% Ficoll 400, and 0.01% denatured salmon sperm DNA. After termination of the incubation, the membrane is washed, initiating at 37°C in 2 x SSC containing 0.5% SDS, and changing the SSC concentration to 0.1 x SSC from the starting level, while varying the SSC temperature to 50°C until the signal from the immobilized DNA becomes distinguishable from the background.

Thus, it is possible to obtain a gene for a thermostable DNA polymerase similar to the DNA polymerase of the present invention of which the DNA polymerase activity is not identical but of the same level as that of the DNA polymerase of the present invention, by introducing into an appropriate microorganism a DNA fragment obtained by a gene amplification reaction using, as a primer, a gene isolated by the present invention or a portion of the base sequence of the gene, with a DNA obtained from one of the above thermophilic archaeobacteria as a template, or a DNA fragment resulting from the thermophilic archaeobacterium by hybridization with the fragment obtained by a gene amplification reaction as a probe, and assaying the DNA polymerase activity in the same manner as above.

The present invention is hereinafter described by means of the following examples, but the scope of the present invention is not limited only to those examples. The % values shown in Examples below mean % by weight.

Example 1(1) Preparation of *Pyrococcus furiosus* Genomic DNA

5 *Pyrococcus furiosus* DSM3638 was cultured in the following manner:

A medium having a composition comprising 1% trypton, 0.5% yeast extract, 1% soluble starch, 3.5% Jamarin S Solid (Jamarin Laboratory), 0.5% Jamarin S Liquid (Jamarin Laboratory), 0.003%  $\text{MgSO}_4$ , 0.001%  $\text{NaCl}$ , 0.0001%  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.0001%  $\text{CoSO}_4$ , 0.0001%  $\text{CaCl}_2 \cdot 7\text{H}_2\text{O}$ , 0.0001%  $\text{ZnSO}_4$ , 0.1 ppm  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ , 0.1 ppm  
10  $\text{KAl}(\text{SO}_4)_2$ , 0.1 ppm  $\text{H}_3\text{BO}_3$ , 0.1 ppm  $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ , and 0.25 ppm  $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$  was placed in a two-liter medium bottle and sterilized at 120°C for 20 minutes. After removal of dissolved oxygen by sparging with nitrogen gas thereinto, the above strain was inoculated into the resulting medium. Thereafter, the medium was cultured by kept standing at 95°C for 16 hours. After termination of the cultivation, cells were harvested by centrifugation.

The harvested cells were then suspended in 4 ml of 0.05 M Tris-HCl (pH 8.0) containing 25% sucrose. To this sus-  
15 pension, 0.8 ml of lysozyme [5 mg/ml, 0.25 M Tris-HCl (pH 8.0)] and 2 ml of 0.2 M EDTA were added and incubated at 20°C for 1 hour. After adding 24 ml of an SET solution [150 mM NaCl, 1 mM EDTA, and 20 mM Tris-HCl (pH 8.0)], 4 ml of 5% SDS and 400  $\mu\text{l}$  of proteinase K (10 mg/ml) were added to the resulting mixture. Thereafter, the resulting mixture was reacted at 37°C for 1 hour. After termination of the reaction, phenol-chloroform extraction and subsequent ethanol precipitation were carried out to prepare about 3.2 mg of genomic DNA.

20

(2) Preparation of Cosmid Protein Library

Four hundred micrograms of the genomic DNA from *Pyrococcus furiosus* DSM3638 was partially digested with *Sau*3A1 and fractionated by size into 35 to 50 kb fractions by density gradient ultracentrifugation method. One micro-  
25 gram of the triple helix cosmid vector (manufactured by Stratagene) was digested with *Xba*I, dephosphorylated using an alkaline phosphatase (manufactured by Takara Shuzo Co., Ltd.), and further digested with *Bam*HI. The resulting treated vector was subjected to ligation after mixing with 140  $\mu\text{g}$  of the above 35 to 50 kb DNA fractions. The genomic DNA fragment from *Pyrococcus furiosus* was packaged into lambda phage particles by *in vitro* packaging method using "GIGAPACK GOLD" (manufactured by Stratagene), to prepare a library. A portion of the obtained library was then trans-  
30 duced into *E. coli* DH5 $\alpha$ MCR. Several transformants out of the resulting transformants were selected to prepare a cosmid DNA. After confirmation of the presence of an insert of appropriate size, about 500 transformants were again selected from the above library, and each was separately cultured in 150 ml of an LB medium (10 g/l trypton, 5 g/l yeast extract, 5 g/l NaCl, pH 7.2) containing 100  $\mu\text{g}/\text{ml}$  ampicillin. The resulting culture was centrifuged, and the harvested cells were suspended in 1 ml of 20 mM Tris-HCl at a pH of 8.0, and the resulting suspension was then heat-treated at  
35 100°C for 10 minutes. Next, ultrasonication was carried out, and a heat treatment was carried out again at 100°C for 10 minutes. The lysate obtained as a supernatant after centrifugation was used as a cosmid protein library.

(3) Assay of DNA Polymerase Activity

40 The DNA polymerase activity was assayed using calf thymus DNA (manufactured by Worthington) activated by DNase I treatment (activated DNA) as a substrate. DNA activation and assay of DNA polymerase activity were carried out by the method described in DNA Polymerase from *Escherichia coli*, 263-276 (authored by C.C. Richardson), published by Harper & Row, edited by D.R. Davis.

An assay of enzyme activity was carried out by the following method. Specifically, 50  $\mu\text{l}$  of a reaction solution [20  
45 mM Tris-HCl (pH 7.7), 15 mM  $\text{MgCl}_2$ , 2 mM 2-mercaptoethanol, 0.2 mg/ml activated DNA, 40  $\mu\text{M}$  each of dATP, dCTP, dGTP and dTTP, 60 nM [ $^3\text{H}$ ]-dTTP (manufactured by Amersham)], containing a sample for assaying its activity, was prepared and reacted at 75°C for 15 minutes. A 40  $\mu\text{l}$  portion of this reaction mixture was then spotted onto a DE paper (manufactured by Whatman) and washed with 5%  $\text{Na}_2\text{HPO}_4$  five times. The remaining radioactivity on the DE paper was assayed using a liquid scintillation counter. The amount of enzyme which incorporated 10 nmol of [ $^3\text{H}$ ]-dTTP per  
50 30 minutes into the substrate DNA, assayed by the above-described enzyme activity assay method, was defined as one unit of the enzyme.

(4) Selection of Cosmid Clones Containing DNA Polymerase Gene

55 A reaction mixture comprising 20 mM Tris-HCl (pH 7.7), 2 mM  $\text{MgCl}_2$ , 2 mM 2-mercaptoethanol, 0.2 mg/ml activated DNA, 40  $\mu\text{M}$  each of dATP, dCTP, dGTP and dTTP, 60 nM [ $^3\text{H}$ ]-dTTP (manufactured by Amersham) was prepared. One  $\mu\text{l}$  of 5 clones each of the respective extracts from the cosmid protein library, namely 5  $\mu\text{l}$  of extracts as for one reaction, was added to 45  $\mu\text{l}$  of this mixture. After the mixture was reacted at 75°C for 15 minutes, a 40  $\mu\text{l}$  portion of

each reaction mixture was spotted onto a DE paper and washed with 5% Na<sub>2</sub>HPO<sub>4</sub> five times. The remaining radioactivity on the DE paper was assayed using a liquid scintillation counter. A group found to have some activities by primary assay, wherein one group consisted of 5 clones, was separated into one clone each from the 5 clones, and then secondary assay was carried out for each clone. Since it had been already known that the cosmid DNA library included clones containing a known DNA polymerase gene by a hybridization test with the gene as a probe, designated as Clone Nos. 57, 154, 162, and 363, 5 clones possessing DNA synthesis activity other than those clones were found as Clone Nos. 41, 153, 264, 462, and 491.

#### (5) Preparation of Restriction Endonuclease Map

Cosmids were isolated from the above 5 clones, and each cosmid was digested with *Bam*HI. When examining the resulting migration patterns, there were demonstrated several mutually common bands, predicting that those 5 clones recombine regions with overlaps and slight shifts. With this finding in mind, the DNA inserts in Clone Nos. 264 and 491 were treated to prepare the restriction endonuclease map. The cosmids prepared from both clones were digested with various restriction endonucleases. As a result of determination for respective cleavage sites of *Kpn*I, *Not*I, *Pst*I, *Sma*I, *Xba*I, and *Xho*I (all manufactured by Takara Shuzo Co., Ltd.), digested into fragments of appropriate sizes, a map as shown in FIG. 1 was obtained.

#### (6) Subcloning of DNA Polymerase Gene

On the basis of the restriction endonuclease map as shown in FIG. 1, various DNA fragments of about 10 kbp in length were cut out from the cosmid derived from clone No. 264 or 491. The fragments were then subcloned into the pTV118N or pTV119N vector (manufactured by Takara Shuzo Co., Ltd.). The resulting transformant with each of the recombinant plasmids was then subjected to assaying of the thermostable DNA polymerase activity, to demonstrate that a gene for production of a highly thermostable DNA polymerase was present an *Xba*I-*Xba*I fragment of about 10 kbp. A plasmid resulting from recombination of the *Xba*I-*Xba*I fragment in the pTV118N vector was then named as plasmid pFU1001, and the *Escherichia coli* JM109 transformed with the plasmid was named as *Escherichia coli* JM109/pFU1001.

#### Example 2

##### Determination of Base Sequence of DNA Fragment Containing Novel DNA Polymerase Gene

The above *Xba*I-*Xba*I fragment, containing the DNA polymerase gene, was again cut out from the plasmid pFU1001 obtained in Example 1 with *Xba*I, and blunt-ended using a DNA blunting kit (manufactured by Takara Shuzo Co., Ltd.). The resultant was then ligated to the new pTV118N vector, previously linearized with *Sma*I, in different orientations to yield plasmids for preparing deletion mutants. The resulting plasmids were named as pFU1002 and pFU1003, respectively. Deletion mutants were sequentially prepared from both ends of the DNA insert using these plasmids. The Kilo-Sequence deletion kit (manufactured by Takara Shuzo Co., Ltd.) applying Henikoff's method (*Gene*, 28, 351-359) was used for the above preparation. The 3'-overhanging type and 5'-overhanging type restriction endonucleases used were *Pst*I and *Xba*I, respectively. The base sequence of the insert was determined by the dideoxy method using the BcaBEST dideoxy sequencing kit (manufactured by Takara Shuzo Co., Ltd.) with the various deletion mutants as templates.

An 8,450 bp sequence in the base sequence determined is shown by SEQ ID NO:5 in Sequence Listing. As a result of analysis of the base sequence, there were revealed six open reading frames (ORFs) capable of encoding proteins, present at positions corresponding to Base Nos. 123-614 (ORF1), 611-1381 (ORF2), 1384-3222 (ORF3), 3225-7013 (ORF4), 7068-7697 (ORF5), and 7711-8385 (ORF6) in the base sequence as shown by SEQ ID NO:5 in Sequence Listing. The restriction endonuclease map of the about 10 kbp *Xba*I-*Xba*I DNA fragment recombined in the plasmid pFU1001 and the location of the above-mentioned ORFs thereon are shown in FIG. 2.

In addition, the thermostable DNA polymerase activity was assayed using the above various deletion mutants. The results demonstrated that the DNA polymerase activity is lost when the deletion involves the ORF3 and ORF4 regions, regardless of whether the deletion started from upstream or downstream. This finding demonstrated that the translation products of the ORF3 and the ORF4 were important in the exhibition of the DNA polymerase activity. The base sequence of the ORF3 is shown by SEQ ID No:2 in Sequence Listing, and the amino acid sequence of the translation product of the ORF3 as deduced from the base sequence is SEQ ID NO:1 in Sequence Listing, respectively. Also, the base sequence of ORF4 is shown by SEQ ID NO:4 in Sequence Listing, and the amino acid sequence of the translation product of ORF4 as deduced from the base sequence is SEQ ID NO:3 in Sequence Listing, respectively.

Example 3Preparation of Purified DNA Polymerase Standard Preparation

5 The *Escherichia coli* JM109/pFU1001 obtained in Example 1 was cultured in 500 ml of an LB medium (10 g/l trypton, 5 g/l yeast extract, 5 g/l NaCl, pH 7.2) containing ampicillin at a concentration of 100 µg/ml. When the culture broth turbidity reached 0.6 in A<sub>600</sub>, an inducer, isopropyl-β-D-thiogalactoside (IPTG) was added and cultured for 16 hours. After harvesting, the harvested cells were suspended in 37 ml of a sonication buffer [50 mM Tris-HCl, pH 8.0, 0.2 mM 2-mercaptoethanol, 10% glycerol, 2.4 mM PMSF (phenylmethanesulfonyl fluoride)] and applied to an ultrasonic dis-

10 rupter. Forty-two milliliters of a crude extract was recovered as a supernatant by centrifugation at 12,000 rpm for 10 minutes, which was then heat-treated at 80°C for 15 minutes. Centrifugation was again carried out at 12,000 rpm for 10 minutes to yield 33 ml of a heat-treated enzyme solution. The above solution was then dialyzed with 800 ml of buffer A [50 mM potassium phosphate, pH 6.5, 2 mM 2-mercaptoethanol, 10% glycerol] as an external dialysis liquid for 2 hours x 4. After dialysis, 32 ml of the enzyme solution was applied to a RESOURCE Q column (manufactured by Pharmacia)

15 which was previously equilibrated with buffer A, and subjected to chromatography using an FPLC system (manufactured by Pharmacia). A development of chromatogram was carried out on a linear concentration gradient from 0 to 500 mM NaCl. A fraction having a DNA polymerase activity was eluted at 340 mM NaCl.

Ten milliliters of an enzyme solution obtained by collecting as an active fraction was desalted and concentrated by ultrafiltration, and dissolved in buffer A + 150 mM NaCl to yield 3.5 ml of an enzyme solution. The resulting enzyme solu-

20 tion was then applied to a Hi Trap Heparin column (manufactured by Pharmacia), previously equilibrated with the same buffer. A chromatogram was developed on a linear concentration gradient from 150 to 650 mM NaCl using an FPLC system, to yield an active fraction eluted at 400 mM NaCl. Five milliliters of this fraction was concentrated to 120 µl of a solution including 50 mM potassium phosphate, pH 6.5, 2 mM 2-mercaptoethanol, and 75 mM NaCl by repeating desalting and concentration using ultrafiltration. The resulting concentrated solution was then applied to a gel filtration

25 column of Superose 6 (manufactured by Pharmacia), previously equilibrated with the same buffer, and eluted with the same buffer. As a result, a fraction having a DNA polymerase activity was eluted at positions corresponding to retention times of 34.7 minutes and 38.3 minutes. It is suggested from the results of comparison with the elution position of molecular weight markers under the same conditions that these activity peaks have molecular weights of about 385 kDa and about 220 kDa, respectively. These molecular weights corresponded to a complex formed by the translation prod-

30 uct of ORF3 and the translation product of ORF4 in a molar ratio of 1:2 and another complex formed by the above translation products in a molar ratio of 1:1, respectively. For the former peak, however, since a possibility that a complex is formed by the two translation products in a 2:2 molar ratio cannot be negated, the molecular weight determination error increases as the molecular weight increases.

Example 4(1) Biochemical Properties of DNA Polymerase

For a DNA polymerase preparation forming a complex of the translation products of ORF3 and ORF4 obtained in

40 Example 3, namely the first DNA polymerase-constituting protein and the second DNA polymerase-constituting protein in a ratio at 1:1, optimum MgCl<sub>2</sub> and KCl concentrations were firstly assayed. The DNA polymerase activity was assayed in a reaction system containing 20 mM Tris-HCl, pH 7.7, 2 mM 2-mercaptoethanol, 0.2 mg/ml activated DNA, and 40 µM each of dATP, dGTP, dCTP and dTTP in the presence of 2 mM MgCl<sub>2</sub>, while the KCl concentration was step by step increased from 0 to 200 mM KCl for each 20 mM increment. As a result, the maximum activity was exhibited at

45 a KCl concentration of 60 mM. Next, the DNA polymerase activity was assayed in the same reaction system but in the presence of 60 mM KCl in this time, while the MgCl<sub>2</sub> concentration was step by step increased from 0.5 to 25 mM MgCl<sub>2</sub> for each 2.5 mM increment, to compare at each concentration. In this case, the maximum activity was exhibited at an MgCl<sub>2</sub> concentration of 10 mM, and alternatively, in the absence of KCl, the maximum activity was exhibited at an MgCl<sub>2</sub> concentration of 17.5 mM.

50 The optimum pH was then assayed. The DNA polymerase activity was assayed at 75°C by using potassium phosphate buffers at various pH levels, and preparing a reaction mixture comprising 20 mM potassium phosphate, 15 mM MgCl<sub>2</sub>, 2 mM 2-mercaptoethanol, 0.2 mg/ml activated DNA, 40 µM each of dATP, dCTP, dGTP and dTTP, and 60 nM [<sup>3</sup>H]-dTTP. The results are shown in FIG. 3, wherein the abscissa indicates the pH, and the ordinate indicates the radioactivity incorporated in high-molecular DNA. As shown in the figure, the DNA polymerase of the present invention

55 exhibited the maximum activity at a pH of 6.5 to 7.0. When Tris-HCl was used in place of potassium phosphate, the activity increased with alkalinity, and the maximum activity was exhibited at a pH of 8.02, the highest pH level used in the assay.

The heat stability of the DNA polymerase of the present invention was assayed as follows: The purified DNA

polymerase was prepared to yield a mixture containing 20 mM Tris-HCl (pH 7.7), 2 mM 2-mercaptoethanol, 10% glycerol, and 0.1% bovine serum albumin, and the resulting mixture was incubated at various temperatures for 30 minutes. The remaining DNA polymerase activity was assayed. The results are shown in FIG. 4, wherein the abscissa indicates the incubation temperature, and the ordinate indicates the remaining activity. As shown in the figure, the present enzyme retained not less than 80% remaining activity even after heat treatment at 80°C for 30 minutes.

In order to compare the modes of inhibition by inhibitors, the modes of inhibition of the DNA polymerase of the present invention and an  $\alpha$ -type DNA polymerase derived from *Pyrococcus furiosus* (Pfu DNA polymerase, manufactured by Stratagene), a known DNA polymerase, were compared using a specific inhibitor of  $\alpha$ -type DNA polymerases, aphidicolin. The activity changes were examined, while the aphidicolin concentration was increased from 0 to 2.0 mM in the presence of 20 mM Tris-HCl, pH 7.7, 15 mM MgCl<sub>2</sub>, 2 mM 2-mercaptoethanol, 0.2 mg/ml activated DNA, and 40  $\mu$ M each of dATP, dGTP, dCTP and dTTP. As a result, the activity of the Pfu DNA polymerase was decreased to 20% of the original activity at 1.0 mM, while the novel DNA polymerase of the present invention was not inhibited at all even at 2.0 mM.

## (2) Primer Extension Reaction

Next, in order to compare the selectivity of the DNA polymerase of the present invention for different forms of substrate DNA, the following template-primer was examined. Aside from the activated DNA used for conventional assay of the activity, those prepared as substrates include a thermal-denatured DNA prepared by treating the activated DNA at 85°C for 5 minutes; M13-HT Primer prepared by annealing a 45-base synthetic deoxyribonucleotide of the sequence as shown by SEQ ID NO:6 in Sequence Listing as a primer to the M13 phage single stranded DNA (M13mp18 ssDNA, manufactured by Takara Shuzo Co., Ltd.); M13-RNA Primer prepared by annealing a 17-base synthetic ribonucleotide of the sequence as shown by SEQ ID NO:7 in Sequence Listing as a primer to the same M13 phage single stranded DNA; Poly dA-Oligo dT prepared by mixing polydeoxyadenosine (Poly dA, manufactured by Pharmacia) and oligodeoxythymidine (Oligo dT, manufactured by Pharmacia) in a 20:1 molar ratio; and Poly A-Oligo dT prepared by mixing polyadenosine (Poly A, manufactured by Pharmacia) and oligodeoxythymidine in a 20:1 molar ratio.

The DNA polymerase activity was assayed using these substrates in place of the activated DNA. The relative activity of each substrate when the activity obtained in the case of using an activated DNA as a substrate is defined as 100 is shown in Table 1. For comparison, the Pfu DNA polymerase and the Taq DNA polymerase derived from *Thermus aquaticus* (TaKaRa Taq, manufactured by Takara Shuzo Co., Ltd.) were also examined in the same manner. As shown in Table 1, in comparison with other DNA polymerases, the novel DNA polymerase of the present invention exhibited higher activity when the substrate used was the M13-HT Primer rather than the activated DNA, demonstrating that the novel DNA polymerase of the present invention is especially suitable for primer extension reaction.

The primer extension activity was further investigated extensively. The M13-HT Primer, previously labeled with [ $\gamma$ -<sup>32</sup>P]-ATP (manufactured by Amersham) and T4 polynucleotide kinase (manufactured by Takara Shuzo Co., Ltd.) at the 5'-end, was used as a substrate. Ten microliters of a reaction mixture [20 mM Tris-HCl (pH 7.7), 15 mM MgCl<sub>2</sub>, 2 mM 2-mercaptoethanol, 270  $\mu$ M each of dATP, dGTP, dCTP and dTTP] containing the above substrate in a final concentration of 0.05  $\mu$ g/ $\mu$ l and various DNA polymerases in amounts providing 0.05 units of activity as assayed with the activated DNA as a substrate was reacted at 75°C for 1, 2, 3, or 4 minutes. After termination of the reaction, 2  $\mu$ l of a reaction stop solution (95% formaldehyde, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) was added, subjected to thermal denaturation treatment at 95°C for 3 minutes. Two microliters of the reaction mixture was then subjected to electrophoresis using polyacrylamide gel containing 8 M urea and subsequently subjected to a preparation of autoradiogram. Also, in order to examine the extension activity in the presence of the activated DNA as a competitor substrate, the activated DNA was added to the above reaction mixture to a final concentration of 0.4  $\mu$ g/ml, and subjected to a preparation of an autoradiogram by the same procedures as described above. The autoradiogram obtained is shown in FIG. 6.

In the figure, Pol, Pfu, and Taq show the results for the DNA polymerase of the present invention, the Pfu DNA polymerase and the Taq DNA polymerase, respectively. In addition, 1, 2, 3, and 4 each indicates reaction time (min). In the figure, the representation "-" and "+" show the results obtained in the absence and in the presence, respectively, of the activated DNA. The lanes G, A, T, and C at the left end of the figure also show the results of electrophoresis of the reaction products obtained by a chain termination reaction by the dideoxy method using the same substrate as above, which were used to estimate the length of each extension product. As shown in the figure, the DNA polymerase of the present invention exhibited superior primer extension activity than those of the Pfu DNA polymerase and the Taq DNA polymerase. It was also shown that the DNA polymerase of the present invention was unlikely to be inhibited by the activated DNA, in contrast to the Taq DNA polymerase, which exhibited relatively higher primer extension activity in the absence of the activated DNA, was markedly inhibited by the addition of the activated DNA in great excess. From the above finding, it was confirmed that the DNA polymerase of the present invention possesses high affinity especially to primer extension type substrates having a form in which a single primer was annealed to a single stranded template

## DNA.

(3) Presence or Absence of Associated Exonuclease Activity

5 The exonuclease activity of the DNA polymerase of the present invention was assessed as follows: As a substrate for 5'→3' exonuclease activity detection, a DNA fragment labeled with <sup>32</sup>P at the 5'-end was prepared by a process comprising digesting a pUC119 vector (manufactured by Takara Shuzo Co., Ltd.) with *Ssp*I (manufactured by Takara Shuzo Co., Ltd.), separating the resulting 386 bp DNA fragment by agarose gel electrophoresis, purifying the fragment, and labeling with [ $\gamma$ -<sup>32</sup>P]-ATP and polynucleotide kinase. Also, as a substrate for 3'→5' exonuclease activity detection, a DNA fragment labeled with <sup>32</sup>P at 3'-end was prepared by a process comprising digesting a pUC119 vector with *Sau*3AI, separating the resulting 341 bp DNA fragment by agarose gel electrophoresis, purifying the fragment, and carrying out a fill-in reaction using [ $\gamma$ -<sup>32</sup>P]-CTP (manufactured by Amersham) and the Klenow fragment (manufactured by Takara Shuzo Co., Ltd.). The labeled DNAs were purified by gel filtration with NICK COLUMN (manufactured by Pharmacia) and used in the subsequent reaction. To a reaction solution [20 mM Tris-HCl (pH 7.7), 15 mM MgCl<sub>2</sub>, 2 mM 2-mercaptoethanol] containing 1 ng of these labeled DNAs, 0.015 units of DNA polymerase was added, and the resulting mixture was reacted at 75°C for 2.5, 5, and 7.5 minutes. The DNAs were precipitated by adding ethanol. The radioactivity existing in the supernatant was assayed using a liquid scintillation counter, and the amount of degradation by the exonuclease activity was calculated. The DNA polymerase of the present invention was shown to possess potent 3'→5' exonuclease activity, while no 5'→3' exonuclease activity was observed. The 3'→5' exonuclease activity of the Pfu DNA polymerase, known to possess potent 3'→5' exonuclease activity, was also assayed in the same manner as above. The results are together shown in FIG. 5.

In the figure, the abscissa indicates the reaction time, and the ordinate indicates the ratio of radioactivity released into the supernatant relative to the radioactivity contained in the entire reaction mixture. Also, the open circles indicate the results for the DNA polymerase of the present invention, and the solid circles indicate those for the Pfu DNA polymerase. As shown in the figure, the DNA polymerase of the present invention showed potent 3'→5' exonuclease activity of the same level as that of the Pfu DNA polymerase, known to possess high accuracy of DNA synthesis owing to high 3'→5' exonuclease activity.

(4) Comparison of Accuracy of DNA Synthesis Reaction

30 The accuracy of DNA synthesis reaction by DNA polymerases was examined using a pUC118 vector (manufactured by Takara Shuzo Co., Ltd.), partially made single stranded (gapped duplex plasmid, as a template. The single stranded pUC118 vector was prepared by the method described in *Molecular Cloning: A Laboratory Manual*, 2nd ed., 4.44-4.48, published by Cold Spring Harbor Laboratory in 1989, edited by T. Maniatis et al., using a helper phage M13KO7 (manufactured by Takara Shuzo Co., Ltd.) with *Escherichia coli* MV1184 (manufactured by Takara Shuzo Co., Ltd.) as a host. The double stranded DNA was prepared by digesting the pUC118 vector with *Pvu*II (manufactured by Takara Shuzo Co., Ltd.), subjecting the digested vector to agarose gel electrophoresis, and recovering a DNA fragment of about 2.8 kbp.

One microgram of the above single stranded DNA and 2  $\mu$ g of the double stranded DNA were mixed to make 180  $\mu$ l of a mixture with sterile distilled water, and the solution was then incubated at 70°C for 10 minutes. Thereafter, twenty microliters of 20 x SSC was added to the resulting mixture, and the mixture was further kept standing at 60°C for 10 minutes. The DNA was recovered by subjecting to ethanol precipitation. A portion thereof was subjected to agarose gel electrophoresis, and it was confirmed that a gapped duplex plasmid was obtained. Thirty microliters of a reaction mixture [10 mM Tris-HCl, pH 8.5, 50 mM KCl, 10 mM MgCl<sub>2</sub>, 1 mM each of dATP, dCTP, dGTP and dTTP], containing an amount one-tenth that of the resulting gapped duplex plasmid was incubated at 70°C for 3 minutes, after which 0.5 units of DNA polymerase was added thereto, and a DNA synthesis reaction was carried out at 70°C for 10 minutes. After termination of the reaction, *Escherichia coli* DH5 $\alpha$  (manufactured by BRL) was transformed using 10  $\mu$ l of the reaction mixture. The resulting transformant was cultured at 37°C for 18 hours on an LB plate containing 100  $\mu$ g/ml ampicillin, 0.1 mM IPTG, and 40  $\mu$ g/ml 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactoside. The white or blue colonies formed on the plate were counted, and the formation rate of white colonies which were resulted from a DNA synthesis error was calculated. As a result, the white colony formation rate (%) was 3.18% when the Taq DNA polymerase was used as the DNA polymerase, in contrast to a lower formation rate of 1.61% when the DNA polymerase of the present invention was used.

(5) Application to PCR

In order to compare the performance of the DNA polymerase of the present invention in PCR with that of the Taq DNA polymerase, PCR was carried out with  $\lambda$ -DNA as a template. The reaction mixture for the DNA polymerase of the

present invention had the following composition: 10 mM Tris-HCl (pH 9.2), 3.5 mM MgCl<sub>2</sub>, 75 mM KCl, 400 μM each of dATP, dCTP, dGTP and dTTP, 0.01% bovine serum albumin (BSA), and 0.1% Triton X-100. The reaction solution for the Taq DNA polymerase had the following composition: 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, and 400 μM each of dATP, dCTP, dGTP and dTTP. Fifty microliters of a reaction mixture containing 5.0 ng/50 μl λ-DNA (manufactured by Takara Shuzo Co., Ltd.), 10 pmol/50 μl each of primer λ1 and primer λ11, and 3.7 units/50 μl DNA polymerase was prepared. The base sequences of the primer λ1 and the primer λ11 are shown by SEQ ID NO:8 and SEQ ID NO:9 in Sequence Listing, respectively. After, a 30-cycle PCR was carried out with the above reaction mixture, wherein one cycle is defined at 98°C for 10 seconds and at 68°C for 10 seconds. Five microliters of the reaction mixture was subjected to agarose gel electrophoresis, and the amplified DNA fragment was confirmed by staining with ethidium bromide. As a result, it was demonstrated that the DNA fragment amplification was not found when the Taq DNA polymerase was used, in contrast to the DNA polymerase of the present invention where amplification of a DNA fragment of about 20 kbp was confirmed.

The experiment was then carried out by changing the primer to the primer λ1 and the primer λ10. The base sequence of the primer λ10 is shown by SEQ ID NO:10 in Sequence Listing. Twenty-five microliters of a reaction mixture having a similar composition to that shown above and containing 2.5 ng of λ-DNA, 10 pmol of the primer λ1 and the primer λ10, respectively, and 3.7 units of DNA polymerase was prepared. The reaction mixture was reacted in 5 cycles under the same reaction conditions as those described above, and 5 μl of the reaction mixture was subjected to agarose gel electrophoresis and stained with ethidium bromide. It was demonstrated that no specific amplification was observed when the Taq DNA polymerase was used, in contrast to the DNA polymerase of the present invention where a DNA fragment of about 15 kbp was amplified.

#### Example 5

##### (1) Construction of Plasmid for Expression of ORF3 Translation Product Alone

PCR was carried out using a mutant plasmid 6-82 as a template, the mutant plasmid being prepared by deleting the portion immediately downstream of the ORF3 from the DNA insert in the plasmid pFU1002 described in Example 2, wherein the ORF1 to the ORF6 were located downstream of the *lac* promoter on the vector and also using a primer M4 (manufactured by Takara Shuzo Co., Ltd) and the primer NO3 whose base sequence is shown by SEQ ID:11 in Sequence Listing. The DNA polymerase used for the PCR was the Pfu DNA polymerase (manufactured by Stratagene), which possessed high accuracy of synthesis reaction. A 25-cycle reaction of 100 μl of a reaction mixture for PCR [20 mM Tris-HCl, pH 8.2, 10 mM KCl, 20 mM MgCl<sub>2</sub>, 6 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.2 mM each of dATP, dCTP, dGTP and dTTP, 1% Triton X-100, 0.01% BSA] containing 1 ng of a template DNA, 25 pmol of each primer, and 2.5 units of the Pfu DNA polymerase was carried out, wherein one cycle is defined as at 94°C for 0.5 minutes, at 55°C for 0.5 minutes and at 72°C for 2 minutes. The amplified DNA fragment of about 2 kbp was digested with *Nco*I and *Sph*I (each manufactured by Takara Shuzo Co., Ltd.) and inserted into between the *Nco*I-*Sph*I sites of the pTV118N vector (manufactured by Takara Shuzo Co., Ltd.) to prepare a plasmid pFU-ORF3. The DNA insert in the above plasmid contains ORF3 alone in translatable conditions.

##### (2) Construction of Plasmid for Expression of ORF4 Translation Product Alone

PCR was carried out using a mutant plasmid 6-2 as a template, the mutant plasmid being prepared by deleting the portion downstream of the center portion of the ORF4 from the DNA insert in the above-described plasmid pFU1002, the primer M4, and the primer NO4 of which the base sequence is shown by SEQ ID NO:12 in Sequence Listing. The reaction was carried out under the same conditions as those for Example 5-(1) described above, except that the template DNA was replaced with the plasmid 6-2, and the primer NO3 was replaced with the primer NO4. A DNA fragment of about 1.6 kbp obtained by digesting the above amplified DNA fragment with *Nco*I and *Nhe*I (manufactured by Takara Shuzo Co., Ltd.), together with an about 3.3 kbp *Nhe*I-*Sal*I fragment, including the latter portion of ORF4, isolated from the above plasmid pFU1002 was inserted between the *Nco*I-*Xho*I sites of a pET15b vector (manufactured by Novagen) to prepare a plasmid pFU-ORF4. The DNA insert in the plasmid contains ORF4 alone in translatable conditions.

##### (3) Reconstitution of DNA Polymerase with ORF3 and ORF4 Translation Products

The *Escherichia coli* JM109 transformed with the above-described plasmid pFU-ORF3, *Escherichia coli* JM109/pFU-ORF3, and the *Escherichia coli* HMS174 transformed with the above-described plasmid pFU-ORF4, *Escherichia coli* HMS174/pFU-ORF4, were separately cultured, and then the translation products of the two ORFs expressed in their cells were purified. The cultivation of the transformants and the preparation of the crude extracts were carried out by the methods described in Example 3. Purification of both translation products was carried out using col-



umns such as RESOURCE Q, HiTrap Heparin, and Superose 6, while the behaviors of the translation products on SDS-PAGE were monitored. It was confirmed that although neither of the ORF translation products thus purified exhibited the DNA polymerase activity when assayed alone, thermostable DNA polymerase activity was exhibited when they were mixed together.

5

# INDUSTRIAL APPLICABILITY

10

The present invention can provide a novel DNA polymerase possessing both high primer extensibility and high 3'→5' exonuclease activity. The enzyme is suitable for its use for PCR method, which is useful for a reagent for genetic engineering investigation. It is also possible to produce the enzyme by genetic engineering using the genes encoding the DNA polymerase of the present invention.

15

20

25

30

35

40

45

50

55

## SEQUENCE LISTING

5 SEQ ID NO:1  
 SEQUENCE LENGTH: 613  
 SEQUENCE TYPE: amino acid  
 10 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULAR TYPE: peptide  
 SEQUENCE DESCRIPTION:  
 15 Met Asp Glu Phe Val Lys Ser Leu Leu Lys Ala Asn Tyr Leu Ile  
                           5                          10                          15  
 Thr Pro Ser Ala Tyr Tyr Leu Leu Arg Glu Tyr Tyr Glu Lys Gly  
 20                          20                          25                          30  
 Glu Phe Ser Ile Val Glu Leu Val Lys Phe Ala Arg Ser Arg Glu  
                           35                          40                          45  
 25 Ser Tyr Ile Ile Thr Asp Ala Leu Ala Thr Glu Phe Leu Lys Val  
                           50                          55                          60  
 Lys Gly Leu Glu Pro Ile Leu Pro Val Glu Thr Lys Gly Gly Phe  
                           65                          70                          75  
 30 Val Ser Thr Gly Glu Ser Gln Lys Glu Gln Ser Tyr Glu Glu Ser  
                           80                          85                          90  
 Phe Gly Thr Lys Glu Glu Ile Ser Gln Glu Ile Lys Glu Gly Glu  
 35                          95                          100                          105  
 Ser Phe Ile Ser Thr Gly Ser Glu Pro Leu Glu Glu Glu Leu Asn  
                           110                          115                          120  
 40 Ser Ile Gly Ile Glu Glu Ile Gly Ala Asn Glu Glu Leu Val Ser  
                           125                          130                          135  
 Asn Gly Asn Asp Asn Gly Gly Glu Ala Ile Val Phe Asp Lys Tyr  
                           140                          145                          150  
 45 Gly Tyr Pro Met Val Tyr Ala Pro Glu Glu Ile Glu Val Glu Glu  
                           155                          160                          165  
 Lys Glu Tyr Ser Lys Tyr Glu Asp Leu Thr Ile Pro Met Asn Pro  
 50                          170                          175                          180  
 Asp Phe Asn Tyr Val Glu Ile Lys Glu Asp Tyr Asp Val Val Phe

55

EP 0 870 832 A1

|    |                 |                     |                         |     |  |     |
|----|-----------------|---------------------|-------------------------|-----|--|-----|
|    |                 | 185                 |                         | 190 |  | 195 |
|    | Asp Val Arg Asn | Val Lys Leu Lys Pro | Pro Lys Val Lys Asn Gly |     |  |     |
| 5  |                 | 200                 |                         | 205 |  | 210 |
|    | Asn Gly Lys Glu | Gly Glu Ile Ile Val | Glu Ala Tyr Ala Ser Leu |     |  |     |
|    |                 | 215                 |                         | 220 |  | 225 |
| 10 | Phe Arg Ser Arg | Leu Lys Lys Leu Arg | Lys Ile Leu Arg Glu Asn |     |  |     |
|    |                 | 230                 |                         | 235 |  | 240 |
|    | Pro Glu Leu Asp | Asn Val Val Asp Ile | Gly Lys Leu Lys Tyr Val |     |  |     |
|    |                 | 245                 |                         | 250 |  | 255 |
| 15 | Lys Glu Asp Glu | Thr Val Thr Ile Ile | Gly Leu Val Asn Ser Lys |     |  |     |
|    |                 | 260                 |                         | 265 |  | 270 |
|    | Arg Glu Val Asn | Lys Gly Leu Ile Phe | Glu Ile Glu Asp Leu Thr |     |  |     |
| 20 |                 | 275                 |                         | 280 |  | 285 |
|    | Gly Lys Val Lys | Val Phe Leu Pro Lys | Asp Ser Glu Asp Tyr Arg |     |  |     |
|    |                 | 290                 |                         | 295 |  | 300 |
| 25 | Glu Ala Phe Lys | Val Leu Pro Asp Ala | Val Val Ala Phe Lys Gly |     |  |     |
|    |                 | 305                 |                         | 310 |  | 315 |
|    | Val Tyr Ser Lys | Arg Gly Ile Leu Tyr | Ala Asn Lys Phe Tyr Leu |     |  |     |
|    |                 | 320                 |                         | 325 |  | 330 |
| 30 | Pro Asp Val Pro | Leu Tyr Arg Arg Gln | Lys Pro Pro Leu Glu Glu |     |  |     |
|    |                 | 335                 |                         | 340 |  | 345 |
|    | Lys Val Tyr Ala | Ile Leu Ile Ser Asp | Ile His Val Gly Ser Lys |     |  |     |
| 35 |                 | 350                 |                         | 355 |  | 360 |
|    | Glu Phe Cys Glu | Asn Ala Phe Ile Lys | Phe Leu Glu Trp Leu Asn |     |  |     |
|    |                 | 365                 |                         | 370 |  | 375 |
| 40 | Gly Asn Val Glu | Thr Lys Glu Glu Glu | Glu Ile Val Ser Arg Val |     |  |     |
|    |                 | 380                 |                         | 385 |  | 390 |
|    | Lys Tyr Leu Ile | Ile Ala Gly Asp Val | Val Asp Gly Val Gly Val |     |  |     |
|    |                 | 395                 |                         | 400 |  | 405 |
| 45 | Tyr Pro Gly Gln | Tyr Ala Asp Leu Thr | Ile Pro Asp Ile Phe Asp |     |  |     |
|    |                 | 410                 |                         | 415 |  | 420 |
|    | Gln Tyr Glu Ala | Leu Ala Asn Leu Leu | Ser His Val Pro Lys His |     |  |     |
| 50 |                 | 425                 |                         | 430 |  | 435 |
|    | Ile Thr Met Phe | Ile Ala Pro Gly Asn | His Asp Ala Ala Arg Gln |     |  |     |

55

|    |                                     |                         |     |
|----|-------------------------------------|-------------------------|-----|
|    | 440                                 | 445                     | 450 |
|    | Ala Ile Pro Gln Pro Glu Phe Tyr Lys | Glu Tyr Ala Lys Pro Ile |     |
| 5  | 455                                 | 460                     | 465 |
|    | Tyr Lys Leu Lys Asn Ala Val Ile Ile | Ser Asn Pro Ala Val Ile |     |
|    | 470                                 | 475                     | 480 |
|    | Arg Leu His Gly Arg Asp Phe Leu Ile | Ala His Gly Arg Gly Ile |     |
| 10 | 485                                 | 490                     | 495 |
|    | Glu Asp Val Val Gly Ser Val Pro Gly | Leu Thr His His Lys Pro |     |
|    | 500                                 | 505                     | 510 |
|    | Gly Leu Pro Met Val Glu Leu Leu Lys | Met Arg His Val Ala Pro |     |
| 15 | 515                                 | 520                     | 525 |
|    | Met Phe Gly Gly Lys Val Pro Ile Ala | Pro Asp Pro Glu Asp Leu |     |
|    | 530                                 | 535                     | 540 |
| 20 | Leu Val Ile Glu Glu Val Pro Asp Val | Val His Met Gly His Val |     |
|    | 545                                 | 550                     | 555 |
|    | His Val Tyr Asp Ala Val Val Tyr Arg | Gly Val Gln Leu Val Asn |     |
|    | 560                                 | 565                     | 570 |
| 25 | Ser Ala Thr Trp Gln Ala Gln Thr Glu | Phe Gln Lys Met Val Asn |     |
|    | 575                                 | 580                     | 585 |
|    | Ile Val Pro Thr Pro Ala Lys Val Pro | Val Val Asp Ile Asp Thr |     |
|    | 590                                 | 595                     | 600 |
| 30 | Ala Lys Val Val Lys Val Leu Asp Phe | Ser Gly Trp Cys         |     |
|    | 605                                 | 610                     |     |

35 SEQ ID NO:2  
 SEQUENCE LENGTH: 1839  
 SEQUENCE TYPE: nucleic acid  
 STRANDEDNESS: double  
 40 TOPOLOGY: linear  
 MOLECULAR TYPE: Genomic DNA  
 SEQUENCE DESCRIPTION:  
 45 ATGGATGAAT TTGTAAATC ACTTCTAAAA GCTAACTATC TAATAACTCC CTCTGCCTAC 60  
 TATCTCTTGA GAGAATACTA TGAAAAAGGT GAATTCTCAA TTGTGGAGCT GGTAATAATT 120  
 GCAAGATCAA GAGAGAGCTA CATAATTACT GATGCTTTAG CAACAGAATT CCTTAAAGTT 180

50

55

AAAGGCCTTG AACCAATTCT TCCAGTGGAA ACAAAGGGGG GTTTTGTTTC CACTGGAGAG 240  
TCCCAAAAAG AGCAGTCTTA TGAAGAGTCT TTTGGGACTA AAGAAGAAAT TTCCCAGGAG 300  
5 ATTAAGAAG GAGAGAGTTT TATTTCCACT GGAAGTGAAC CACTTGAAGA GGAGCTCAAT 360  
AGCATTGGAA TTGAGGAAAT TGGGGCAAAT GAAGAGTTAG TTTCTAATGG AAATGACAAT 420  
GGTGGAGAGG CAATTGTCTT TGACAAATAT GGCTATCCAA TGGTATATGC TCCAGAAGAA 480  
ATAGAGGTTG AGGAGAAGGA GTACTCGAAG TATGAAGATC TGACAATACC CATGAACCCC 540  
10 GACTTCAATT ATGTGGAAAT AAAGGAAGAT TATGATGTTG TCTTCGATGT TAGGAATGTA 600  
AAGCTGAAGC CTCCTAAGGT AAAGAACGGT AATGGGAAGG AAGGTGAAAT AATTGTTGAA 660  
GCTTATGCTT CTCTCTTCAG GAGTAGGTTG AAGAAGTTAA GGAAAATACT AAGGGAAAAT 720  
CCTGAATTGG ACAATGTTGT TGATATTGGG AAGCTGAAGT ATGTGAAGGA AGATGAAACC 780  
15 GTGACAATAA TAGGGCTTGT CAATTCCAAG AGGGAAGTGA ATAAAGGATT GATATTTGAA 840  
ATAGAAGATC TCACAGGAAA GGTTAAAGTT TTCTGCCGA AAGATTCGGA AGATTATAGG 900  
GAGGCATTTA AGGTTCTTCC AGATGCCGTC GTCGCTTTTA AGGGGGTGTA TTCAAAGAGG 960  
20 GGAATTTTGT ACGCCAACAA GTTTTACCTT CCAGACGTTT CCCTCTATAG GAGACAAAAG 1020  
CCTCCACTGG AAGAGAAAGT TTATGCTATT CTCATAAGTG ATATACACGT CGGAAGTAAA 1080  
GAGTTCTGCG AAAATGCCTT CATAAAGTTC TTAGAGTGGC TCAATGGAAA CGTTGAAACT 1140  
AAGGAAGAGG AAGAAATCGT GAGTAGGGTT AAGTATCTAA TCATTGCAGG AGATGTTGTT 1200  
25 GATGGTGTG GCGTTTATCC GGGCCAGTAT GCCGACTTGA CGATTCCAGA TATATTCGAC 1260  
CAGTATGAGG CCCTCGCAA CTTTCTCTCT CACGTTCTTA AGCACATAAC AATGTTTCATT 1320  
GCCCCAGGAA ACCACGATGC TGCTAGGCAA GCTATTCCCC AACCAGAATT CTACAAAGAG 1380  
TATGCAAAC CTATATACAA GCTCAAGAAC GCCGTGATAA TAAGCAATCC TGCTGTAATA 1440  
30 AGACTACATG GTAGGGACTT TCTGATAGCT CATGGTAGGG GGATAGAGGA TGTCGTTGGA 1500  
AGTGTTCCTG GGTGACCCA TCACAAGCCC GGCCTCCCA TGGTTGAACT ATTGAAGATG 1560  
AGGCATGTAG CTCCAATGTT TGGAGGAAAG GTTCCAATAG CTCCTGATCC AGAAGATTTG 1620  
CTTGTTATAG AAGAAGTTCC TGATGTAGTT CACATGGGTC ACGTTCACGT TTACGATGCG 1680  
35 GTAGTTTATA GGGGAGTTCA GCTGGTTAAC TCCGCCACCT GGCAGGCTCA GACCGAGTTC 1740  
CAGAAGATGG TGAACATAGT TCCAACGCCT GCAAAGGTTT CCGTTGTTGA TATTGATACT 1800  
GCAAAGTTG TCAAGGTTTT GGACTTTAGT GGGTGGTGC 1839

40

SEQ ID NO:3

SEQUENCE LENGTH: 1263

SEQUENCE TYPE: amino acid

45

STRANDEDNESS: single

TOPOLOGY: linear

50

55

MOLECULAR TYPE: peptide

SEQUENCE DESCRIPTION:

|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| 5  | Met | Glu | Leu | Pro | Lys | Glu | Ile | Glu | Glu | Tyr | Phe | Glu | Met | Leu | Gln |  |
|    |     |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
|    | Arg | Glu | Ile | Asp | Lys | Ala | Tyr | Glu | Ile | Ala | Lys | Lys | Ala | Arg | Ser |  |
| 10 |     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
|    | Gln | Gly | Lys | Asp | Pro | Ser | Thr | Asp | Val | Glu | Ile | Pro | Gln | Ala | Thr |  |
|    |     |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
|    | Asp | Met | Ala | Gly | Arg | Val | Glu | Ser | Leu | Val | Gly | Pro | Pro | Gly | Val |  |
| 15 |     |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
|    | Ala | Gln | Arg | Ile | Arg | Glu | Leu | Leu | Lys | Glu | Tyr | Asp | Lys | Glu | Ile |  |
|    |     |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
| 20 | Val | Ala | Leu | Lys | Ile | Val | Asp | Glu | Ile | Ile | Glu | Gly | Lys | Phe | Gly |  |
|    |     |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
|    | Asp | Phe | Gly | Ser | Lys | Glu | Lys | Tyr | Ala | Glu | Gln | Ala | Val | Arg | Thr |  |
| 25 |     |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
|    | Ala | Leu | Ala | Ile | Leu | Thr | Glu | Gly | Ile | Val | Ser | Ala | Pro | Leu | Glu |  |
|    |     |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| 30 | Gly | Ile | Ala | Asp | Val | Lys | Ile | Lys | Arg | Asn | Thr | Trp | Ala | Asp | Asn |  |
|    |     |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
|    | Ser | Glu | Tyr | Leu | Ala | Leu | Tyr | Tyr | Ala | Gly | Pro | Ile | Arg | Ser | Ser |  |
|    |     |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
| 35 | Gly | Gly | Thr | Ala | Gln | Ala | Leu | Ser | Val | Leu | Val | Gly | Asp | Tyr | Val |  |
|    |     |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
|    | Arg | Arg | Lys | Leu | Gly | Leu | Asp | Arg | Phe | Lys | Pro | Ser | Gly | Lys | His |  |
| 40 |     |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
|    | Ile | Glu | Arg | Met | Val | Glu | Glu | Val | Asp | Leu | Tyr | His | Arg | Ala | Val |  |
|    |     |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| 45 | Ser | Arg | Leu | Gln | Tyr | His | Pro | Ser | Pro | Asp | Glu | Val | Arg | Leu | Ala |  |
|    |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
|    | Met | Arg | Asn | Ile | Pro | Ile | Glu | Ile | Thr | Gly | Glu | Ala | Thr | Asp | Asp |  |
|    |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     | 225 |  |
| 50 | Val | Glu | Val | Ser | His | Arg | Asp | Val | Glu | Gly | Val | Glu | Thr | Asn | Gln |  |
|    |     |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |  |

55

|    |                 |                     |                     |     |
|----|-----------------|---------------------|---------------------|-----|
|    | Leu Arg Gly Gly | Ala Ile Leu Val Leu | Ala Glu Gly Val Leu | Gln |
|    |                 | 245                 | 250                 | 255 |
| 5  | Lys Ala Lys Lys | Leu Val Lys Tyr Ile | Asp Lys Met Gly Ile | Asp |
|    |                 | 260                 | 265                 | 270 |
|    | Gly Trp Glu Trp | Leu Lys Glu Phe Val | Glu Ala Lys Glu Lys | Gly |
| 10 |                 | 275                 | 280                 | 285 |
|    | Glu Glu Ile Glu | Glu Ser Glu Ser Lys | Ala Glu Glu Ser Lys | Val |
|    |                 | 290                 | 295                 | 300 |
| 15 | Glu Thr Arg Val | Glu Val Glu Lys Gly | Phe Tyr Tyr Lys Leu | Tyr |
|    |                 | 305                 | 310                 | 315 |
|    | Glu Lys Phe Arg | Ala Glu Ile Ala Pro | Ser Glu Lys Tyr Ala | Lys |
|    |                 | 320                 | 325                 | 330 |
| 20 | Glu Ile Ile Gly | Gly Arg Pro Leu Phe | Ala Gly Pro Ser Glu | Asn |
|    |                 | 335                 | 340                 | 345 |
|    | Gly Gly Phe Arg | Leu Arg Tyr Gly Arg | Ser Arg Val Ser Gly | Phe |
| 25 |                 | 350                 | 355                 | 360 |
|    | Ala Thr Trp Ser | Ile Asn Pro Ala Thr | Met Val Leu Val Asp | Glu |
|    |                 | 365                 | 370                 | 375 |
| 30 | Phe Leu Ala Ile | Gly Thr Gln Met Lys | Thr Glu Arg Pro Gly | Lys |
|    |                 | 380                 | 385                 | 390 |
|    | Gly Ala Val Val | Thr Pro Ala Thr Thr | Ala Glu Gly Pro Ile | Val |
|    |                 | 395                 | 400                 | 405 |
| 35 | Lys Leu Lys Asp | Gly Ser Val Val Arg | Val Asp Asp Tyr Asn | Leu |
|    |                 | 410                 | 415                 | 420 |
|    | Ala Leu Lys Ile | Arg Asp Glu Val Glu | Glu Ile Leu Tyr Leu | Gly |
| 40 |                 | 425                 | 430                 | 435 |
|    | Asp Ala Ile Ile | Ala Phe Gly Asp Phe | Val Glu Asn Asn Gln | Thr |
|    |                 | 440                 | 445                 | 450 |
| 45 | Leu Leu Pro Ala | Asn Tyr Val Glu Glu | Trp Trp Ile Gln Glu | Phe |
|    |                 | 455                 | 460                 | 465 |
|    | Val Lys Ala Val | Asn Glu Ala Tyr Glu | Val Glu Leu Arg Pro | Phe |
|    |                 | 470                 | 475                 | 480 |
| 50 | Glu Glu Asn Pro | Arg Glu Ser Val Glu | Glu Ala Ala Glu Tyr | Leu |
|    |                 | 485                 | 490                 | 495 |

55

|    |   |         |
|----|---|---------|
|    | Glu Val Asp Pro Glu Phe Leu Ala Lys Met Leu Tyr Asp Pro Leu |         |
|    | 500   | 505 510 |
| 5  | Arg Val Lys Pro Pro Val Glu Leu Ala Ile His Phe Ser Glu Ile |         |
|    | 515   | 520 525 |
|    | Leu Glu Ile Pro Leu His Pro Tyr Tyr Thr Leu Tyr Trp Asn Thr |         |
| 10 | 530   | 535 540 |
|    | Val Asn Pro Lys Asp Val Glu Arg Leu Trp Gly Val Leu Lys Asp |         |
|    | 545   | 550 555 |
|    | Lys Ala Thr Ile Glu Trp Gly Thr Phe Arg Gly Ile Lys Phe Ala |         |
| 15 | 560   | 565 570 |
|    | Lys Lys Ile Glu Ile Ser Leu Asp Asp Leu Gly Ser Leu Lys Arg |         |
|    | 575   | 580 585 |
| 20 | Thr Leu Glu Leu Leu Gly Leu Pro His Thr Val Arg Glu Gly Ile |         |
|    | 590   | 595 600 |
|    | Val Val Val Asp Tyr Pro Trp Ser Ala Ala Leu Leu Thr Pro Leu |         |
| 25 | 605   | 610 615 |
|    | Gly Asn Leu Glu Trp Glu Phe Lys Ala Lys Pro Phe Tyr Thr Val |         |
|    | 620   | 625 630 |
|    | Ile Asp Ile Ile Asn Glu Asn Asn Gln Ile Lys Leu Arg Asp Arg |         |
| 30 | 635   | 640 645 |
|    | Gly Ile Ser Trp Ile Gly Ala Arg Met Gly Arg Pro Glu Lys Ala |         |
|    | 650   | 655 660 |
| 35 | Lys Glu Arg Lys Met Lys Pro Pro Val Gln Val Leu Phe Pro Ile |         |
|    | 665   | 670 675 |
|    | Gly Leu Ala Gly Gly Ser Ser Arg Asp Ile Lys Lys Ala Ala Glu |         |
| 40 | 680   | 685 690 |
|    | Glu Gly Lys Ile Ala Glu Val Glu Ile Ala Phe Phe Lys Cys Pro |         |
|    | 695   | 700 705 |
|    | Lys Cys Gly His Val Gly Pro Glu Thr Leu Cys Pro Glu Cys Gly |         |
| 45 | 710   | 715 720 |
|    | Ile Arg Lys Glu Leu Ile Trp Thr Cys Pro Lys Cys Gly Ala Glu |         |
|    | 725   | 730 735 |
| 50 | Tyr Thr Asn Ser Gln Ala Glu Gly Tyr Ser Tyr Ser Cys Pro Lys |         |
|    | 740   | 745 750 |

55



|    |   |      |      |
|----|---|------|------|
|    | Cys Asn Val Lys Leu Lys Pro Phe Thr Lys Arg Lys Ile Lys Pro |      |      |
|    | 755   | 760  | 765  |
| 5  | Ser Glu Leu Leu Asn Arg Ala Met Glu Asn Val Lys Val Tyr Gly |      |      |
|    | 770   | 775  | 780  |
|    | Val Asp Lys Leu Lys Gly Val Met Gly Met Thr Ser Gly Trp Lys |      |      |
| 10 | 785   | 790  | 795  |
|    | Ile Ala Glu Pro Leu Glu Lys Gly Leu Leu Arg Ala Lys Asn Glu |      |      |
|    | 800   | 805  | 810  |
|    | Val Tyr Val Phe Lys Asp Gly Thr Ile Arg Phe Asp Ala Thr Asp |      |      |
| 15 | 815   | 820  | 825  |
|    | Ala Pro Ile Thr His Phe Arg Pro Arg Glu Ile Gly Val Ser Val |      |      |
|    | 830   | 835  | 840  |
| 20 | Glu Lys Leu Arg Glu Leu Gly Tyr Thr His Asp Phe Glu Gly Lys |      |      |
|    | 845   | 850  | 855  |
|    | Pro Leu Val Ser Glu Asp Gln Ile Val Glu Leu Lys Pro Gln Asp |      |      |
| 25 | 860   | 865  | 870  |
|    | Val Ile Leu Ser Lys Glu Ala Gly Lys Tyr Leu Leu Arg Val Ala |      |      |
|    | 875   | 880  | 885  |
|    | Arg Phe Val Asp Asp Leu Leu Glu Lys Phe Tyr Gly Leu Pro Arg |      |      |
| 30 | 890   | 895  | 900  |
|    | Phe Tyr Asn Ala Glu Lys Met Glu Asp Leu Ile Gly His Leu Val |      |      |
|    | 905   | 910  | 915  |
| 35 | Ile Gly Leu Ala Pro His Thr Ser Ala Gly Ile Val Gly Arg Ile |      |      |
|    | 920   | 925  | 930  |
|    | Ile Gly Phe Val Asp Ala Leu Val Gly Tyr Ala His Pro Tyr Phe |      |      |
| 40 | 935   | 940  | 945  |
|    | His Ala Ala Lys Arg Arg Asn Cys Asp Gly Asp Glu Asp Ser Val |      |      |
|    | 950   | 955  | 960  |
| 45 | Met Leu Leu Leu Asp Ala Leu Leu Asn Phe Ser Arg Tyr Tyr Leu |      |      |
|    | 965   | 970  | 975  |
|    | Pro Glu Lys Arg Gly Gly Lys Met Asp Ala Pro Leu Val Ile Thr |      |      |
|    | 980   | 985  | 990  |
| 50 | Thr Arg Leu Asp Pro Arg Glu Val Asp Ser Glu Val His Asn Met |      |      |
|    | 995   | 1000 | 1005 |

55

|    |   |      |      |
|----|---|------|------|
|    | Asp Val Val Arg Tyr Tyr Pro Leu Glu Phe Tyr Glu Ala Thr Tyr |      |      |
|    | 1010  | 1015 | 1020 |
| 5  | Glu Leu Lys Ser Pro Lys Glu Leu Val Arg Val Ile Glu Gly Val |      |      |
|    | 1025  | 1030 | 1035 |
|    | Glu Asp Arg Leu Gly Lys Pro Glu Met Tyr Tyr Gly Ile Lys Phe |      |      |
| 10 | 1040  | 1045 | 1050 |
|    | Thr His Asp Thr Asp Asp Ile Ala Leu Gly Pro Lys Met Ser Leu |      |      |
|    | 1055  | 1060 | 1065 |
|    | Tyr Lys Gln Leu Gly Asp Met Glu Glu Lys Val Lys Arg Gln Leu |      |      |
| 15 | 1070  | 1075 | 1080 |
|    | Thr Leu Ala Glu Arg Ile Arg Ala Val Asp Gln His Tyr Val Ala |      |      |
|    | 1085  | 1090 | 1095 |
| 20 | Glu Thr Ile Leu Asn Ser His Leu Ile Pro Asp Leu Arg Gly Asn |      |      |
|    | 1100  | 1105 | 1110 |
|    | Leu Arg Ser Phe Thr Arg Gln Glu Phe Arg Cys Val Lys Cys Asn |      |      |
| 25 | 1115  | 1120 | 1125 |
|    | Thr Lys Tyr Arg Arg Pro Pro Leu Asp Gly Lys Cys Pro Val Cys |      |      |
|    | 1130  | 1135 | 1140 |
| 30 | Gly Gly Lys Ile Val Leu Thr Val Ser Lys Gly Ala Ile Glu Lys |      |      |
|    | 1145  | 1150 | 1155 |
|    | Tyr Leu Gly Thr Ala Lys Met Leu Val Ala Asn Tyr Asn Val Lys |      |      |
|    | 1160  | 1165 | 1170 |
| 35 | Pro Tyr Thr Arg Gln Arg Ile Cys Leu Thr Glu Lys Asp Ile Asp |      |      |
|    | 1175  | 1180 | 1185 |
|    | Ser Leu Phe Glu Tyr Leu Phe Pro Glu Ala Gln Leu Thr Leu Ile |      |      |
| 40 | 1190  | 1195 | 1200 |
|    | Val Asp Pro Asn Asp Ile Cys Met Lys Met Ile Lys Glu Arg Thr |      |      |
|    | 1205  | 1210 | 1215 |
| 45 | Gly Glu Thr Val Gln Gly Gly Leu Leu Glu Asn Phe Asn Ser Ser |      |      |
|    | 1220  | 1225 | 1230 |
|    | Gly Asn Asn Gly Lys Lys Ile Glu Lys Lys Glu Lys Lys Ala Lys |      |      |
|    | 1235  | 1240 | 1245 |
| 50 | Glu Lys Pro Lys Lys Lys Lys Val Ile Ser Leu Asp Asp Phe Phe |      |      |
|    | 1250  | 1255 | 1260 |

55

Ser Lys Arg

5 SEQ ID NO:4  
 SEQUENCE LENGTH: 3789  
 SEQUENCE TYPE: nucleic acid  
 STRANDEDNESS: double  
 10 TOPOLOGY: linear  
 MOLECULAR TYPE: Genomic DNA  
 SEQUENCE DESCRIPTION:  
 ATGGAGCTTC CAAAGGAAAT TGAGGAGTAT TTTGAGATGC TTCAAAGGGA AATTGACAAA 60  
 15 GCTTACGAGA TTGCTAAGAA GGCTAGGAGT CAGGGTAAAG ACCCCTCAAC CGATGTTGAG 120  
 ATTCCCCAGG CTACAGACAT GGCTGGAAGA GTTGAAGAGCT TAGTTGGCCC TCCCGGAGTT 180  
 GCTCAGAGAA TTAGGGAGCT TTTAAAAGAG TATGATAAGG AAATTGTTGC TTAAAGATA 240  
 20 GTTGATGAGA TAATTGAGGG CAAATTTGGT GATTTTGGAA GTAAAGAGAA GTACGCTGAA 300  
 CAGGCTGTAA GGACAGCCTT GGCAATATTA ACTGAGGGTA TTGTTTCTGC TCCACTTGAG 360  
 GGTATAGCTG ATGTTAAAAT CAAGCGAAAC ACCTGGGCTG ATAACCTCTGA ATACCTCGCC 420  
 CTTTACTATG CTGGGCCAAT TAGGAGTTCT GGTGGAAGCT CTCAAGCTCT CAGTGTACTT 480  
 25 GTTGGTGATT ACGTTAGGCG AAAGCTTGGC CTTGATAGGT TTAAGCCAAG TGGGAAGCAT 540  
 ATAGAGAGAA TGTTGAGGA AGTTGACCTC TATCATAGAG CTGTTTCAAG GCTTCAATAT 600  
 CATCCCTCAC CTGATGAAGT GAGATTAGCA ATGAGGAATA TTCCCATAGA AATCACTGGT 660  
 GAAGCCACTG ACGATGTGGA GGTTCCTCAT AGAGATGTAG AGGGAGTTGA GACAAATCAG 720  
 30 CTGAGAGGAG GAGCGATCCT AGTTTTGGCG GAGGGTGTTT TCCAGAAGGC TAAAAAGCTC 780  
 GTGAAATACA TTGACAAGAT GGGGATTGAT GGATGGGAGT GGCTTAAAGA GTTTGTAGAG 840  
 GCTAAAGAAA AAGGTGAAGA AATCGAAGAG AGTGAAAGTA AAGCCGAGGA GTCAAAAGTT 900  
 35 GAAACAAGGG TGGAGGTAGA GAAGGGATTC TACTACAAGC TCTATGAGAA ATTTAGGGCT 960  
 GAGATTGCCC CAAGCGAAAA GTATGCAAAG GAAATAATTG GTGGGAGGCC GTTATTCGCT 1020  
 GGACCCTCGG AAAATGGGGG ATTTAGGCTT AGATATGGTA GAAGTAGGGT GAGTGGATTT 1080  
 GCAACATGGA GCATAAATCC AGCAACAATG GTTTTGGTTG ACGAGTTCTT GGCCATTGGA 1140  
 40 ACTCAAATGA AAACCGAGAG GCCTGGGAAA GGTGCAGTAG TGAATCCAGC AACAACCGCT 1200  
 GAAGGGCCGA TTGTTAAGCT AAAGGATGGG AGTGTTGTTA GGTTGATGA TTACAACTTG 1260  
 GCCCTCAAAA TAAGGGATGA AGTCGAAGAG ATACTTTATT TGGGAGATGC AATCATAGCC 1320  
 TTTGGAGACT TTGTGGAGAA CAATCAAACCT CTCCTTCCTG CAACTATGT AGAGGAGTGG 1380  
 45 TGGATCCAAG AGTTCGTAAA GGCCGTTAAT GAGGCATATG AAGTTGAGCT TAGACCCTTT 1440  
 GAGGAAAATC CCAGGGAGAG CGTTGAGGAA GCAGCAGAGT ACCTTGAAGT TGACCCAGAA 1500

50

55

TTCTTGGCTA AGATGCTTTA CGATCCTCTA AGGGTTAAGC CTCCCGTGGA GCTAGCCATA 1560  
 CACTTCTCGG AAATCCTGGA AATTCCTCTC CACCATACT ACACCCTTTA TTGGAATACT 1620  
 5 GTAAATCCTA AAGATGTTGA AAGACTTTGG GGAGTATTAA AAGACAAGGC CACCATAGAA 1680  
 TGGGGCACTT TCAGAGGTAT AAAGTTTGCA AAGAAAATTG AAATTAGCCT GGACGACCTG 1740  
 GGAAGTCTTA AGAGAACCCT AGAGCTCCTG GGACTTCCTC ATACGGTAAG AGAAGGGATT 1800  
 GTAGTGGTTG ATTATCCGTG GAGTGCAGCT CTTCTCACTC CATTGGGCAA TCTTGAATGG 1860  
 10 GAGTTTAAGG CCAAGCCCTT CTACACTGTA ATAGACATCA TTAACGAGAA CAATCAGATA 1920  
 AAGCTCAGGG ACAGGGGAAT AAGCTGGATA GGGGCAAGAA TGGGAAGGCC AGAGAAGGCA 1980  
 AAAGAAAGAA AAATGAAGCC ACCTGTTCAA GTCCTCTTCC CAATTGGCTT GGCAGGGGGT 2040  
 TCTAGCAGAG ATATAAAGAA GGCTGCTGAA GAGGGAAAAA TAGCTGAAGT TGAGATTGCT 2100  
 15 TTCTTCAAGT GTCCGAAGTG TGGCCATGTA GGGCCTGAAA CTCTCTGTCC CGAGTGTGGG 2160  
 ATTAGGAAAG AGTTGATATG GACATGTCCC AAGTGTGGGG CTGAATACAC CAATTCCCAG 2220  
 GCTGAGGGGT ACTCGTATTC ATGTCCAAAG TGCAATGTGA AGCTAAAGCC ATTCACAAAG 2280  
 20 AGGAAGATAA AGCCCTCAGA GCTCTTAAAC AGGGCCATGG AAAACGTGAA GGTTTATGGA 2340  
 GTTGACAAGC TTAAGGGCGT AATGGGAATG ACTTCTGGCT GGAAGATTGC AGAGCCGCTG 2400  
 GAGAAAGGTC TTTTGAGAGC AAAAAATGAA GTTTACGTCT TTAAGGATGG AACCATAAGA 2460  
 TTTGATGCCA CAGATGCTCC AATAACTCAC TTTAGGCCTA GGGAGATAGG AGTTTCAGTG 2520  
 25 GAAAAGCTGA GAGAGCTTGG CTACACCCAT GACTTCGAAG GGAAACCTCT GGTGAGTGAA 2580  
 GACCAGATAG TTGAGCTTAA GCCCAAGAT GTAATCCTCT CAAAGGAGGC TGGCAAGTAC 2640  
 CTCTTAAGAG TGGCCAGGTT TGTGATGAT CTTCTTGAGA AGTTCTACGG ACTTCCCAGG 2700  
 TTCTACAACG CCGAAAAAAT GGAGGATTTA ATTGGTCACC TAGTGATAGG ATTGGCCCCT 2760  
 30 CACACTTCAG CCGGAATCGT GGGGAGGATA ATAGGCTTTG TAGATGCTCT GGTGGCTAC 2820  
 GCTCACCCCT ACTTCCATGC GGCCAAGAGA AGGAACTGTG ATGGAGATGA GGATAGTGTA 2880  
 ATGCTACTCC TTGATGCCCT ATTGAAGTTC TCCAGATACT ACCTCCCCGA AAAAAGAGGA 2940  
 35 GGAAAAATGG ACGCTCCTCT TGTCAATAAC ACGAGGCTTG ATCCAAGAGA GGTGGACAGT 3000  
 GAAGTGCACA ACATGGATGT CGTTAGATAC TATCCATTAG AGTTCTATGA AGCAACTTAC 3060  
 GAGCTTAAAT CACCAAAGGA ACTTGTGAGA GTTATAGAGG GAGTTGAAGA TAGATTAGGA 3120  
 AAGCCTGAAA TGTATTACGG AATAAAGTTC ACCCACGATA CCGACGACAT AGCTCTAGGA 3180  
 40 CCAAAGATGA GCCTCTACAA GCAGTTGGGA GATATGGAGG AGAAAGTGAA GAGGCAATTG 3240  
 ACATTGGCAG AGAGAATTAG AGCTGTGGAT CAACACTATG TTGCTGAAAC AATCCTCAAC 3300  
 TCCCCTTAA TTCCCGACTT GAGGGGTAAC CTAAGGAGCT TTAGTAGACA AGAATTTTCGC 3360  
 TGTGTGAAGT GTAACACAAA GTACAGAAGG CCGCCCTTGG ATGGAAAATG CCCAGTCTGT 3420  
 45 GGAGGAAAGA TAGTGCTGAC AGTTAGCAAA GGAGCCATTG AAAAGTACTT GGGGACTGCC 3480  
 AAGATGCTCG TAGCTAACTA CAACGTAAAG CCATATACAA GGCAGAGAAT ATGCTTGACG 3540

50

55

GAGAAGGATA TTGATTCACT CTTTGAGTAC TTATTCCCAG AAGCCCAGTT AACGCTCATT 3600  
 GTAGATCCAA ACGACATCTG TATGAAAATG ATCAAGGAAA GAACGGGGGA AACAGTTCAA 3660  
 5 GGAGGCCTGC TTGAGAACTT TAATTCCTCT GGAAATAATG GGAAGAAAAT AGAGAAGAAG 3720  
 GAGAAAAAGG CAAAGGAAAA GCCTAAAAAG AAGAAAGTTA TAAGCTTGGA CGACTTCTTC 3780  
 TCCAAACGC 3789

10 SEQ ID NO:5

SEQUENCE LENGTH: 8450

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

15 TOPOLOGY: linear

MOLECULAR TYPE: Genomic DNA

SEQUENCE DESCRIPTION:

20 CATAACTAAA TTATTACATT TAGTTATATG GATGGGGGAA AAATTAACAA CATGTGTTAT 60  
 GTTTCCTCTG GAAAATTGAT CTATAATAAT CTAGGAGCAC AATTCCAAT GGAGGGTCAT 120  
 CAATGAACGA AGGTGAACAT CAAATAAAGC TTGACGAGCT ATTGCGAAAAG TTGCTCCGAG 180  
 CTAGGAAGAT ATTCAAAAAC AAAGATGTCC TTAGGCATAG CTATACTCCC AAGGATCTAC 240  
 25 CTCACAGACA TGAGCAAATA GAAACTCTCG CCCAAATTTT AGTACCAGTT CTCAGAGGAG 300  
 AAACCTCCATC AACATATTC GTTTATGGGA AGACTGGAAC TGGAAAGACT GTAAGTGTAA 360  
 AATTTGTAAC TGAAGAGCTG AAAAGAATAT CTGAAAAATA CAACATTCCA GTTGATGTGA 420  
 TCTACATTAA TTGTGAGATT GTCGATACTC ACTATAGAGT TCTTGCTAAC ATAGTTAACT 480  
 30 ACTTCAAAGA TGAGACTGGG ATTGAAGTTC CAATGGTAGG TTGGCCTACC GATGAAGTTT 540  
 ACGCAAAGCT TAAGCAGGTT ATAGATATGA AGGAGAGGTT TGTGATAATT GTGTTGGATG 600  
 AAATTGACAA GTGGTAAAGA AGAGTGGTGA TGAGGTTCTC TATTCATTAA CAAGAATAAA 660  
 TACTGAACCT AAAAGGGCTA AAGTGAGTGT AATTGGTATA TCAAACGACC TTAAATTTAA 720  
 35 AGAGTATCTA GATCCAAGAG TTCTCTCAAG TTTGAGTGAG GAAGAGGTGG TATCCCACC 780  
 CTATGATGCA AATCAGCTTA GGGATATACT GACCCAAAGA GCTGAAGAGG CCTTTTATCC 840  
 TGGGGTTTTA GACGAAGGTG TGATTCCCCT CTGTGCAGCA TTAGCTGCTA GAGAGCATGG 900  
 40 AGATGCAAGA AAGGCACTTG ACCTTCTAAG AGTTGCAGGG GAAATAGCGG AAAGAGAAGG 960  
 GGCAAGTAAA GTAAGTAAA AGCATGTTTG GAAAGCCCAG GAAAAGATTG AACAGGACAT 1020  
 GATGGAGGAG GTAATAAAAA CTCTACCCCT TCAGTCAAAA GTTCTCCTCT ATGCCATAGT 1080  
 TCTTTTGGAC GAAAACGGCG ATTTACCAGC AAATACTGGG GATGTTTACG CTGTTTATAG 1140  
 45 GGAATTGTGC GAGTACATTG ACTTGAACC TCTCACCCAA AGAAGGATAA GTGATCTAAT 1200  
 TAATGAGCTT GACATGCTTG GAATAATAAA TGCAAAAGTT GTTAGTAAGG GGAGATATGG 1260

50

55

GAGGACAAAG GAAATAAGGC TTAACGTTAC CTCATATAAG ATAAGAAATG TGCTGAGATA 1320  
 TGATTACTCT ATTCAGCCCC TCCTCACAAT TTCCCTTAAG AGTGAGCAGA GGAGGTTGAT 1380  
 5 CTAATGGATG AATTTGTAAA ATCACTTCTA AAAGCTAACT ATCTAATAAC TCCCTCTGCC 1440  
 TACTATCTCT TGAGAGAATA CTATGAAAAA GGTGAATTCT CAATTGTGGA GCTGGTAAAA 1500  
 TTTGCAAGAT CAAGAGAGAG CTACATAATT ACTGATGCTT TAGCAACAGA ATTCCTTAAA 1560  
 GTTAAAGGCC TTGAACCAAT TCTTCCAGTG GAAACAAAGG GGGGTTTTGT TTCCACTGGA 1620  
 10 GAGTCCCCAA AAGAGCAGTC TTATGAAGAG TCTTTTGGGA CTAAAGAAGA AATTTCCCAG 1680  
 GAGATTAAAG AAGGAGAGAG TTTTATTTCC ACTGGAAGTG AACCCTTGA AGAGGAGCTC 1740  
 AATAGCATTG GAATTGAGGA AATTGGGGCA AATGAAGAGT TAGTTTCTAA TGGAAATGAC 1800  
 AATGGTGGAG AGGCAATTGT CTTTGACAAA TATGGCTATC CAATGGTATA TGCTCCAGAA 1860  
 15 GAAATAGAGG TTGAGGAGAA GGAGTACTCG AAGTATGAAG ATCTGACAAT ACCCATGAAC 1920  
 CCCGACTTCA ATTATGTGGA AATAAAGGAA GATTATGATG TTGTCTTCGA TGTTAGGAAT 1980  
 GTAAAGCTGA AGCCTCCTAA GGTAAAGAAC GGTAATGGGA AGGAAGGTGA AATAATTGTT 2040  
 20 GAAGCTTATG CTTCTCTCTT CAGGAGTAGG TTGAAGAAGT TAAGGAAAAT ACTAAGGGAA 2100  
 AATCCTGAAT TGGACAATGT TGTTGATATT GGAAGCTGA AGTATGTGAA GGAAGATGAA 2160  
 ACCGTGACAA TAATAGGGCT TGTCAATTCC AAGAGGGAAG TGAATAAAGG ATTGATATTT 2220  
 GAAATAGAAG ATCTCACAGG AAAGGTTAAA GTTTTCTTGC CGAAAGATTC GGAAGATTAT 2280  
 25 AGGGAGGCAT TTAAGGTTCT TCCAGATGCC GTCGTCGCTT TTAAGGGGGT GTATTCAAAG 2340  
 AGGGGAATTT TGTACGCCAA CAAGTTTTAC CTTCCAGACG TTCCCCTCTA TAGGAGACAA 2400  
 AAGCCTCCAC TGAAGAGAA AGTTTATGCT ATTCTCATAA GTGATATACA CGTCGGAAGT 2460  
 AAAGAGTTCT GCGAAAATGC CTTCATAAAG TTCTTAGAGT GGCTCAATGG AAACGTTGAA 2520  
 30 ACTAAGGAAG AGGAAGAAAT CGTGAGTAGG GTTAAGTATC TAATCATTGC AGGAGATGTT 2580  
 GTTGATGGTG TTGGCGTTTA TCCGGGCCAG TATGCCGACT TGACGATTCC AGATATATTC 2640  
 GACCAGTATG AGGCCCTCGC AAACCTTCTC TCTCACGTTT CTAAGCACAT AACAATGTTC 2700  
 35 ATTGCCCCAG GAAACCACGA TGCTGCTAGG CAAGCTATTC CCCAACCAGA ATTCTACAAA 2760  
 GAGTATGCAA AACCTATATA CAAGCTCAAG AACGCCGTGA TAATAAGCAA TCCTGCTGTA 2820  
 ATAAGACTAC ATGGTAGGGA CTTTCTGATA GCTCATGGTA GGGGGATAGA GGATGTCGTT 2880  
 GGAAGTGTTT CTGGGTTGAC CCATCACAAG CCCGGCCTCC CAATGGTTGA ACTATTGAAG 2940  
 40 ATGAGGCATG TAGCTCCAAT GTTTGGAGGA AAGGTTCCAA TAGCTCCTGA TCCAGAAGAT 3000  
 TTGCTTGTTA TAGAAGAAGT TCCTGATGTA GTTCACATGG GTCACGTTCA CGTTTACGAT 3060  
 GCGGTAGTTT ATAGGGGAGT TCAGCTGGTT AACTCCGCCA CCTGGCAGGC TCAGACCGAG 3120  
 45 TTCCAGAAGA TGGTGAACAT AGTTCCAACG CCTGCAAAGG TTCCCGTTGT TGATATTGAT 3180  
 ACTGCAAAAG TTGTCAAGGT TTTGGACTTT AGTGGGTGGT GCTGATGGAG CTTCCAAAGG 3240  
 AAATTGAGGA GTATTTTGAG ATGCTTCAAA GGGAAATTGA CAAAGCTTAC GAGATTGCTA 3300

AGAAGGCTAG GAGTCAGGGT AAAGACCCCT CAACCGATGT TGAGATTCCC CAGGCTACAG 3360  
 ACATGGCTGG AAGAGTTGAG AGCTTAGTTG GCCCTCCCGG AGTTGCTCAG AGAATTAGGG 3420  
 5 AGCTTTTAAA AGAGTATGAT AAGGAAATTG TTGCTTTAAA GATAGTTGAT GAGATAATTG 3480  
 AGGGCAAATT TGGTGATTTT GGAAGTAAAG AGAAGTACGC TGAACAGGCT GTAAGGACAG 3540  
 CCTTGGCAAT ATTAAGTGAAG GGTATTGTTT CTGCTCCACT TGAGGGTATA GCTGATGTTA 3600  
 AAATCAAGCG AAACACCTGG GCTGATAACT CTGAATACCT CGCCCTTTAC TATGCTGGGC 3660  
 10 CAATTAGGAG TTCTGGTGGA ACTGCTCAAG CTCTCAGTGT ACTTGTGGT GATTACGTTA 3720  
 GCGGAAAGCT TGGCCTTGAT AGGTTTAAAG CAAGTGGGAA GCATATAGAG AGAATGGTTG 3780  
 AGGAAGTTGA CCTCTATCAT AGAGCTGTTT CAAGGCTTCA ATATCATCCC TCACCTGATG 3840  
 AAGTGAGATT AGCAATGAGG AATATTCCCA TAGAAATCAC TGGTGAAGCC ACTGACGATG 3900  
 15 TGGAGGTTTC CCATAGAGAT GTAGAGGGAG TTGAGACAAA TCAGCTGAGA GGAGGAGCGA 3960  
 TCCTAGTTTT GCGGAGGGT GTTCTCCAGA AGGCTAAAAA GCTCGTGAAG TACATTGACA 4020  
 AGATGGGGAT TGATGGATGG GAGTGGCTTA AAGAGTTTGT AGAGGCTAAA GAAAAAGGTG 4080  
 20 AAGAAATCGA AGAGAGTGAA AGTAAAGCCG AGGAGTCAAA AGTTGAAACA AGGGTGGAGG 4140  
 TAGAGAAGGG ATTCTACTAC AAGCTCTATG AGAAATTTAG GGCTGAGATT GCCCCAAGCG 4200  
 AAAAGTATGC AAAGGAAATA ATTGGTGGGA GGCCGTTATT CGCTGGACCC TCGGAAATG 4260  
 GGGGATTTAG GCTTAGATAT GGTAGAAGTA GGGTGAGTGG ATTTGCAACA TGGAGCATAA 4320  
 25 ATCCAGCAAC AATGGTTTTG GTTGACGAGT TCTTGGCCAT TGGAACTCAA ATGAAAACCG 4380  
 AGAGGCCTGG GAAAGGTGCA GTAGTGACTC CAGCAACAAC CGCTGAAGGG CCGATTGTTA 4440  
 AGCTAAAGGA TGGGAGTGTT GTTAGGGTTG ATGATTACAA CTTGGCCCTC AAAATAAGGG 4500  
 ATGAAGTCGA AGAGATACTT TATTTGGGAG ATGCAATCAT AGCCTTTGGA GACTTTGTGG 4560  
 30 AGAACAATCA AACTCTCCTT CCTGCAAACT ATGTAGAGGA GTGGTGGATC CAAGAGTTG 4620  
 TAAAGGCCGT TAATGAGGCA TATGAAGTTG AGCTTAGACC CTTTGAAGAA AATCCCAGGG 4680  
 AGAGCGTTGA GGAAGCAGCA GAGTACCTTG AAGTTGACCC AGAATTCTTG GCTAAGATGC 4740  
 TTTACGATCC TCTAAGGGTT AAGCCTCCCG TGGAGCTAGC CATACACTTC TCGGAAATCC 4800  
 35 TGGAAATTCC TCTCCACCCA TACTACACCC TTTATTGGAA TACTGTAAAT CCTAAAGATG 4860  
 TTGAAAGACT TTGGGGAGTA TTAAGAGACA AGGCCACCAT AGAATGGGGC ACTTTCAGAG 4920  
 GTATAAAGTT TGCAAGAAA ATTGAAATTA GCCTGGACGA CCTGGGAAGT CTTAAGAGAA 4980  
 40 CCCTAGAGCT CCTGGGACTT CCTCATACGG TAAGAGAAGG GATTGTAGTG GTTGATTATC 5040  
 CGTGGAGTGC AGCTCTTCTC ACTCCATTGG GCAATCTTGA ATGGGAGTTT AAGGCCAAGC 5100  
 CCTTCTACAC TGTAATAGAC ATCATTAACG AGAACAATCA GATAAAGCTC AGGGACAGGG 5160  
 GAATAAGCTG GATAGGGGCA AGAATGGGAA GGCCAGAGAA GGCAAAAGAA AGAAAAATGA 5220  
 45 AGCCACCTGT TCAAGTCCTC TTCCCAATTG GCTTGGCAGG GGGTTCTAGC AGAGATATAA 5280  
 AGAAGGCTGC TGAAGAGGGA AAAATAGCTG AAGTTGAGAT TGCTTTCTTC AAGTGTCCGA 5340

50

55

AGTGTGGCCA TGTAGGGCCT GAAACTCTCT GTCCCGAGTG TGGGATTAGG AAAGAGTTGA 5400  
 TATGGACATG TCCCAAGTGT GGGGCTGAAT ACACCAATTC CCAGGCTGAG GGGTACTCGT 5460  
 5 ATTCATGTCC AAAGTGCAAT GTGAAGCTAA AGCCATTAC AAAGAGGAAG ATAAAGCCCT 5520  
 CAGAGCTCTT AACAGGGCC ATGGAACG TGAAGGTTA TGGAGTTGAC AAGCTTAAGG 5580  
 GCGTAATGGG AATGACTTCT GGCTGGAAGA TTGCAGAGCC GCTGGAGAAA GGTCTTTTGA 5640  
 GAGCAAAAAA TGAAGTTTAC GTCTTTAAGG ATGGAACCAT AAGATTTGAT GCCACAGATG 5700  
 10 CTCCAATAAC TCACTTTAGG CCTAGGGAGA TAGGAGTTT AGTGGAAG CTGAGAGAGC 5760  
 TTGGCTACAC CCATGACTTC GAAGGGAAAC CTCTGGTGAG TGAAGACCAG ATAGTTGAGC 5820  
 TTAAGCCCCA AGATGTAATC CTCTCAAAGG AGGCTGGCAA GTACCTCTTA AGAGTGGCCA 5880  
 GGTGTGTTGA TGATCTTCTT GAGAAGTTCT ACGGACTTCC CAGGTTCTAC AACGCCGAAA 5940  
 15 AAATGGAGGA TTTAATTGGT CACCTAGTGA TAGGATTGGC CCCTCACACT TCAGCCGGAA 6000  
 TCGTGGGGAG GATAATAGGC TTTGTAGATG CTCTGGTTGG CTACGCTCAC CCCTACTTCC 6060  
 ATGCGGCCAA GAGAAGGAAC TGTGATGGAG ATGAGGATAG TGTAATGCTA CTCCTTGATG 6120  
 20 CCCTATTGAA CTTCTCCAGA TACTACCTCC CCGAAAAAAG AGGAGGAAAA ATGGACGCTC 6180  
 CTCTTGTCAT AACCACGAGG CTTGATCCAA GAGAGGTGGA CAGTGAAGTG CACAACATGG 6240  
 ATGTCGTTAG ATACTATCCA TTAGAGTTCT ATGAAGCAAC TTACGAGCTT AAATCACCAA 6300  
 AGGAACCTGT GAGAGTTATA GAGGGAGTTG AAGATAGATT AGGAAAGCCT GAAATGTATT 6360  
 25 ACGGAATAAA GTTACCCAC GATACCGACG ACATAGCTCT AGGACCAAAG ATGAGCCTCT 6420  
 ACAAGCAGTT GGGAGATATG GAGGAGAAAG TGAAGAGGCA ATTGACATTG GCAGAGAGAA 6480  
 TTAGAGCTGT GGATCAACAC TATGTTGCTG AAACAATCCT CAACTCCAC TTAATTCCCG 6540  
 ACTTGAGGGG TAACCTAAGG AGCTTTACTA GACAAGAATT TCGCTGTGTG AAGTGTAAAC 6600  
 30 CAAAGTACAG AAGGCCGCCC TTGGATGGAA AATGCCAGT CTGTGGAGGA AAGATAGTGC 6660  
 TGACAGTTAG CAAAGGAGCC ATTGAAAAGT ACTTGGGGAC TGCCAAGATG CTCGTAGCTA 6720  
 ACTACAACGT AAAGCCATAT ACAAGGCAGA GAATATGCTT GACGGAGAAG GATATTGATT 6780  
 CACTCTTTGA GTACTTATTC CCAGAAGCCC AGTTAACGCT CATTGTAGAT CCAAACGACA 6840  
 35 TCTGTATGAA AATGATCAAG GAAAGAACGG GGGAAACAGT TCAAGGAGGC CTGCTTGAGA 6900  
 ACTTTAATTC CTCTGGAAAT AATGGGAAGA AAATAGAGAA GAAGGAGAAA AAGGCAAAGG 6960  
 AAAAGCCTAA AAAGAAGAAA GTTATAAGCT TGGACGACTT CTTCTCCAAA CGCTGACCAC 7020  
 40 AACTTTTAAG TTCTTTCTTG AGAATAAATT CCCAGGTGGC TTAGAGAATG AAGATTGTGT 7080  
 GGTGTGGTCA TGCCTGCTTC TTGGTGGAGG ATAGGGGGAC TAAGATACTA ATCGATCCAT 7140  
 ACCCAGACGT TGATGAAGAC AGAATAGGCA AGGTCGATTA CATTCTAGTT ACCCAGAGC 7200  
 ACATGGATCA CTACGGTAAG ACCCCACTAA TAGCAAAGCT CAGTGATGCC GAGGTTATAG 7260  
 45 GGCCGAAAAC AGTTTATCTC ATGGCAATAA GTGATGGGCT AACAAAGGTC AGAGAGATAG 7320  
 AGGTGGGACA GGAAATCGAG CTGGGAGATA TTAGGGTTAG GGCATTTTTC ACAGAGCATC 7380



CAACAAGCCA GTATCCCCTG GGATATCTAA TTGAAGGAAG CAAAAGAGTG GCTCACTTGG 7440  
GAGATACATA CTACAGTCCA GCTTTTACAG AGTTGAGGGG AAAGGTTGAT GTTCTTTTGG 7500  
5 TTCCAATAGG TGGGAAGTCC ACCGCTAGTG TAAGGGAGGC TCGGATATA GTGGAGATGA 7560  
TAAGGCCCAG GATAGCAGTT CCAATGCACT ATGGAACGTA CAGCGAGGCC GATCCTGAAG 7620  
AGTTCAAGAA GGAGCTCCAA AAAAGGCGCA TATGGGTTTT AGTAAAGGAT CTTAAGCCCT 7680  
ATGAGGGTTT TGAAATCTGA AGGTGTTTCA ATGCTAAATA CTGAGCTCTT AACCACTGGA 7740  
10 GTCAAGGGGT TAGATGAGCT TTTAGGTGGT GGAGTTGCTA AGGGAGTAAT ACTCCAAGTT 7800  
TACGGGCCAT TTGCCACCGG GAAGACAAC TTTGCAATGC AGGTTGGATT ATTGAATGAG 7860  
GGAAAAGTGG CTTATGTTGA TACTGAGGGG GGATTCTCCC CCGAAAGGTT AGCTCAAATG 7920  
GCAGAATCAA GGAACCTGGA TGTGGAGAAA GCACTTGAAA AGTTCGTGAT ATTCGAACCT 7980  
15 ATGGATTTAA ACGAGCAAAG ACAGGTAATT GCGAGGTTGA AAAATATCGT GAATGAAAAG 8040  
TTTTCTTTAG TTGTGGTCGA CTCCTTTACG GCCCATTATA GAGCGGAGGG GAGTAGAGAG 8100  
TATGGAGAAC TTTCCAAGCA ACTCCAAGTT CTTCACTGGA TTGCCAGAAG AAAAAACGTT 8160  
GCCGTTATAG TTGTCAATCA AGTTTATTAC GATTCAAAC CAGGAATTCT TAAACCAATA 8220  
20 GCTGAGCACA CCCTGGGGTA CAAAACAAAG GACATCCTCC GCTTTGAAAG GCTTAGGGTT 8280  
GGAGTGAGAA TTGCAGTTCT GGAAAGGCAT AGGTTTAGGC CAGAGGGTGG GATGGTATAC 8340  
TTCAAAATAA CAGATAAAGG ATTGGAGGAT GTAAAAACG AAGATTAGAG CCTGTCTAG 8400  
25 ACCTCCTGGG CAATCCTCAG CGTTGCCTTA TAGAGCTTCT CACTAATAAT 8450

SEQ ID NO:6

30 SEQUENCE LENGTH: 45

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

35 MOLECULAR TYPE: other nucleic acid (synthetic DNA)

SEQUENCE DESCRIPTION:

CCGGAACCGC CTCCCTCAGA GCCGCCACCC TCAGAACCGC CACCC

45

40 SEQ ID NO:7

SEQUENCE LENGTH: 17

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

45 TOPOLOGY: linear

MOLECULAR TYPE: other nucleic acid (synthetic RNA)

50

55

## SEQUENCE DESCRIPTION:

GUUUUCCCAG UCACGAC

17

5

SEQ ID NO:8

SEQUENCE LENGTH: 23

SEQUENCE TYPE: nucleic acid

10

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULAR TYPE: other nucleic acid (synthetic DNA)

SEQUENCE DESCRIPTION:

15

GATGAGTTCG TGTCCGTACA ACT

23

SEQ ID NO:9

SEQUENCE LENGTH: 22

20

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULAR TYPE: other nucleic acid (synthetic DNA)

25

SEQUENCE DESCRIPTION:

ACAAAGCCAG CCGGAATATC TG

22

30

SEQ ID NO:10

SEQUENCE LENGTH: 22

SEQUENCE TYPE: nucleic acid

35

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULAR TYPE: other nucleic acid (synthetic DNA)

SEQUENCE DESCRIPTION:

40

TACAATACGA TGCCCCGTTA AG

22

SEQ ID NO:11

SEQUENCE LENGTH: 32

45

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

50

55

TOPOLOGY: linear

MOLECULAR TYPE: other nucleic acid (synthetic DNA)

5 SEQUENCE DESCRIPTION:

CAGAGGAGGT TGATCCCATG GATGAATTG TA

32

SEQ ID NO:12

10 SEQUENCE LENGTH: 32

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

15 MOLECULAR TYPE: other nucleic acid (synthetic DNA)

SEQUENCE DESCRIPTION:

TTTAGTGGGT GGTGCCCATG GAGCTTCCAA AG

32

20

## 25 Claims

1. A DNA polymerase characterized in that said DNA polymerase possesses the following properties:

- 30 1) exhibiting higher polymerase activity when assayed by using as a substrate a complex resulting from primer annealing to a single stranded template DNA, as compared to the case where an activated DNA is used as a substrate;
- 2) possessing a 3'→5' exonuclease activity;
- 3) being capable of amplifying a DNA fragment of about 20 kbp, in the case where polymerase chain reaction (PCR) is carried out using λ-DNA as a template under the following conditions:
- 35 PCR conditions:

- (a) a composition of reaction mixture: containing 10 mM Tris-HCl (pH 9.2), 3.5 mM MgCl<sub>2</sub>, 75 mM KCl, 400 μM each of dATP, dCTP, dGTP and dTTP, 0.01% bovine serum albumin, 0.1% Triton X-100, 5.0 ng/50 μl λ-DNA, 10 pmole/50 μl primer λ1 (SEQ ID NO:8 in Sequence Listing), primer λ11 (SEQ ID NO:9 in Sequence Listing), and 3.7 units/50 μl DNA polymerase;
- 40 (b) reaction conditions: carrying out a 30-cycle PCR, wherein one cycle is defined as at 98°C for 10 seconds and at 68°C for 10 minutes.

- 45 2. The DNA polymerase according to claim 1, characterized in that said DNA polymerase exhibits a lower error rate in DNA synthesis as compared to Taq DNA polymerase.
3. The DNA polymerase according to claim 1 or 2, wherein the molecular weight as determined by gel filtration method is about 220 kDa or about 385 kDa.
- 50 4. The DNA polymerase according to any one of claims 1 to 3, characterized in that said DNA polymerase exhibits an activity under coexistence of two kinds of DNA polymerase-constituting protein, a first DNA polymerase-constituting protein and a second DNA polymerase-constituting protein.
- 55 5. The DNA polymerase according to claim 4, characterized in that the molecular weights of said first DNA polymerase-constituting protein and said second DNA polymerase-constituting protein are about 90,000 Da and about 140,000 Da as determined by SDS-PAGE, respectively.
6. The DNA polymerase according to claim 4 or 5, characterized in that said first DNA polymerase-constituting protein

which constitutes the DNA polymerase according to claim 4 or 5 comprises the amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in said amino acid sequence.

7. The DNA polymerase according to claim 4 or 5, characterized in that said second DNA polymerase-constituting protein which constitutes the DNA polymerase according to claim 4 or 5 comprises the amino acid sequence as shown by SEQ ID NO:3 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in said amino acid sequence.
8. The DNA polymerase according to claim 4 or 5, characterized in that said first DNA polymerase-constituting protein which constitutes the DNA polymerase according to claim 4 or 5 comprises the amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in said amino acid sequence, and that said second DNA polymerase-constituting protein which constitutes the DNA polymerase according to claim 4 or 5 comprises the amino acid sequence as shown by SEQ ID NO:3 in Sequence Listing, or is a functional equivalent thereof possessing substantially the same activity which results from deletion, insertion, addition or substitution of one or more amino acids in said amino acid sequence.
9. A first DNA polymerase-constituting protein which constitutes the DNA polymerase according to claim 4 or 5, wherein said first DNA polymerase-constituting protein comprises the amino acid sequence as shown by SEQ ID NO:1, or an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in said amino acid sequence as a functional equivalent thereof possessing substantially the same activity.
10. A second DNA polymerase-constituting protein which constitutes the DNA polymerase according to claim 4 or 5, wherein said second DNA polymerase-constituting protein comprises the amino acid sequence as shown by SEQ ID NO:3, or an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in said amino acid sequence as a functional equivalent thereof possessing substantially the same activity.
11. A DNA containing a base sequence encoding the first DNA polymerase-constituting protein according to claim 9, characterized in that said DNA comprises an entire sequence of a base sequence encoding the amino acid sequence as shown by SEQ ID NO:1 in Sequence Listing, or a partial sequence thereof, or that said DNA encodes a protein having an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence of SEQ ID NO:1 and possessing a function as the first DNA polymerase-constituting protein.
12. A DNA containing a base sequence encoding the first DNA polymerase-constituting protein according to claim 9, characterized in that said DNA comprises an entire sequence of the base sequence as shown by SEQ ID NO:2 in Sequence Listing or a partial sequence thereof, or that said DNA comprises a base sequence capable of hybridizing thereto under stringent conditions.
13. A DNA containing a base sequence encoding the second DNA polymerase-constituting protein according to claim 10, characterized in that said DNA comprises an entire sequence of a base sequence encoding the amino acid sequence as shown by SEQ ID NO:3, or a partial sequence thereof, or that said DNA encodes a protein having an amino acid sequence resulting from deletion, insertion, addition or substitution of one or more amino acids in the amino acid sequence of SEQ ID NO:3 and possessing a function as the second DNA polymerase-constituting protein.
14. A DNA containing a base sequence encoding the second DNA polymerase-constituting protein according to claim 10, characterized in that said DNA comprises an entire sequence of the base sequence as shown by SEQ ID NO:4 in Sequence Listing or a partial sequence thereof, or that said DNA comprises a base sequence capable of hybridizing thereto under stringent conditions.
15. A method for producing a DNA polymerase, characterized in that the method comprises culturing a transformant containing both gene encoding the first DNA polymerase-constituting protein according to claim 11 or 12, and gene encoding the second DNA polymerase-constituting protein according to claim 13 or 14, and collecting the DNA polymerase from the resulting culture.

16. A method for producing a DNA polymerase, characterized in that the method comprises culturing a transformant containing gene encoding the first DNA polymerase-constituting protein according to claim 11 or 12, and a transformant containing gene encoding the second DNA polymerase-constituting protein according to claim 13 or 14, separately; mixing DNA polymerase-constituting proteins contained in the resulting culture; and collecting the DNA polymerase.

5

10

15

20

25

30

35

40

45

50

55




FIG. 1




FIG. 2





FIG. 3





F I G. 4




FIG. 5




FIG. 6

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/03869

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b>  |   |  |
|---|---|--|
| Int. C1 <sup>6</sup> C12N15/54, C12N9/12  |   |  |
| According to International Patent Classification (IPC) or to both national classification and IPC   |   |  |
| <b>B. FIELDS SEARCHED</b>   |   |  |
| Minimum documentation searched (classification system followed by classification symbols)   |   |  |
| Int. C1 <sup>6</sup> C12N15/54, C12N9/12  |   |  |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched   |   |  |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  |   |  |
| CAS ONLINE, BIOSIS, WPI/WPI,L   |   |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |   |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages  | Relevant to claim No.                              |
| A   | Anal. Biochem. 231(1) 1995 Ju Jingyue et al.<br>"Design and synthesis of fluorescence energy transfer dye-labeled primers and their application for DNA sequencing and analysis" p. 131-140 | 1 - 16   |
| A   | WO, 9426766, A (Barnes, Wayne M.),<br>November 24, 1994 (24. 11. 94)<br>& US, 543619, A & EP, 693078, A   | 1 - 16   |
|   | WO, 9317127, A (Oregon State Board of Higher Education),<br>September 2, 1993 (02. 09. 93)<br>& US, 5470724, A  | 1 - 16   |
| A   | J. Clin. Chem. Clin. Biochem. 28(1) 1990 Linz, Ute et al. "Systematic studies on paramaters influencing the performance of the polymerase chain reaction" p. 5-13                           | 1 - 16   |
| X/A   | WO, 9209689, A (Stratagene),  | 1 - 16   |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.  |   |  |
| * Special categories of cited documents:<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document but published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"A" document member of the same patent family |   |  |
| Date of the actual completion of the international search   |   | Date of mailing of the international search report |
| April 1, 1997 (01. 04. 97)  |   | April 15, 1997 (15. 04. 97)                        |
| Name and mailing address of the ISA/<br>Japanese Patent Office  |   | Authorized officer                                 |
| Facsimile No.   |   | Telephone No.                                      |

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/03869

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
|           | June 11, 1992 (11. 06. 92) (Family: none)  |                       |
| A         | EP, 669401, A (Hoffman La Roche Inc.),<br>August 30, 1995 (30. 08. 95)<br>& JP, 8038198, A & US, 5512462, A  | 1 - 16                |
| A         | WO, 9516028, A (Stratagene),<br>June 15, 1995 (15. 06. 95)<br>& US, 5556772, A   | 1 - 16                |
| X/AL      | Nucleic Acids Res. 20(7) 1992 Forterre, Patrick<br>"The DNA polymerase from the archaeobacterium<br>pyrococcus furiosus does not testify for a<br>specific relationship between archaeobacteria<br>and eukaryotes" p. 1881 | 1/2-16                |
| X/A       | Gene 108(1) 1991 Lundberg, Kelly S. et al.<br>"High-fidelity amplification using a<br>thermostable DNA polymerase isolated from<br>pyrococcus furiosus" p. 1-6   | 1-2/3-16              |
| A         | J. Bacteriol. 177(8) 1995 Uemori, Takashi et al.<br>"The hyperthermophilic archaeon pyrodictium<br>ocultium has two alpha-like DNA polymerase"<br>p. 2164-2177   | 1 - 16                |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)